[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2584
1. Xiao L, Luxi S, Ying T, Yizhi L, Lingyun W, Quan P: Diagnosis of unknown nonhematological tumors by bone marrow biopsy: a retrospective analysis of 10,112 samples. J Cancer Res Clin Oncol; 2009 May;135(5):687-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of unknown nonhematological tumors by bone marrow biopsy: a retrospective analysis of 10,112 samples.
  • PURPOSE: To investigate how unselected bone marrow (BM) biopsy examinations could help in the diagnosis of clinically unknown nonhematological tumors.
  • (1) the frequency of BM involvement arising from clinically unknown nonhematological malignancies, (2) the clinical indication for BM biopsy examination in cases with tumor BM metastasis, (3) the primary sites of the metastatic tumors, and (4) the advantage of plastic-embedded biopsy sections over paraffin-embedded samples and the complementarity of biopsy with aspiration smears.
  • In cases with metastatic tumors, the nonhemocyte-related changes, such as skeletal pain (25%) and bone destruction (5%), were considerably higher than in those without metastasis (3.7 and 0.32%, respectively; P < 0.001).
  • Primary lesions were documented antemortem in 50 of the 101 biopsy-positive cases (49.5%); the most frequent being in the lung, gastric tract, and breast.
  • The frequency of metastatic tumors based on aspiration smears when the positive results for biopsy sections were used as a reference was 74.3%.
  • All the 101 sections with metastatic tumors showed various degrees of myelofibrosis.
  • Skeletal pain and bone destruction are critical indications for susceptible patients to undergo BM examination.
  • [MeSH-major] Bone Marrow / pathology. Neoplasms / diagnosis. Neoplasms / pathology
  • [MeSH-minor] Anemia / pathology. Atrophy. Biopsy, Needle. Bone and Bones / pathology. Carcinoma, Small Cell / pathology. Female. Humans. Lung Neoplasms / pathology. Male. Neoplasm Metastasis / pathology. Ovarian Neoplasms / pathology. Pain / pathology. Retrospective Studies. Splenomegaly

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 1989 Feb;103(2):225-6 [2926274.001]
  • [Cites] Hum Pathol. 1994 Aug;25(8):781-8 [7520018.001]
  • [Cites] Am J Hematol. 1986 Aug;22(4):381-9 [3728456.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2403-13 [7922993.001]
  • [Cites] Am J Surg Pathol. 1989 Apr;13(4):329-34 [2648880.001]
  • [Cites] Prostate. 1994 Aug;25(2):108-14 [7518596.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):500-1 [2183639.001]
  • [Cites] J Postgrad Med. 1990 Oct;36(4):194-8 [2132243.001]
  • [Cites] Patol Pol. 1989;40(2):205-9 [2637981.001]
  • [Cites] Acta Oncol. 1991;30(5):587-91 [1654064.001]
  • [Cites] Iryo. 1970 Jul;24(7):585-90 [5458299.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):897-903 [16126867.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):903-11 [16935969.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1759-61 [10738237.001]
  • [Cites] Joint Bone Spine. 2004 May;71(3):224-9 [15182795.001]
  • [Cites] Arch Intern Med. 1964 Aug;114:213-21 [14160114.001]
  • [Cites] Arch Pathol Lab Med. 2005 Apr;129(4):497-501 [15794673.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2795-7 [7872720.001]
  • [Cites] Jpn J Med. 1987 Feb;26(1):58-64 [3573409.001]
  • [Cites] J Cancer Res Clin Oncol. 1988;114(4):425-8 [3410881.001]
  • (PMID = 18956213.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


2. Rodela TM, Wright PA: Characterization of diurnal urea excretion in the mangrove killifish, Rivulus marmoratus. J Exp Biol; 2006 Jul;209(Pt 14):2696-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An unusual characteristic of nitrogen excretion in the ammoniotelic mangrove killifish Rivulus marmoratus is that urea is excreted (J(urea)) in a distinct diurnal pattern, whereas ammonia is excreted (J(amm)) at a steady rate.
  • In this study we tested the hypothesis that the diurnal pattern in R. marmoratus is an endogenously generated pattern that is characterized as a circadian rhythm.
  • This hypothesis was tested by measuring J(urea) and J(amm) following manipulation of feeding or lighting regimes.
  • In contrast, there was no significant pattern in J(amm).
  • Fed fish (12:12 L:D) demonstrated a diurnal pattern in both J(urea) and J(amm) with up to an eightfold increase in excretion rates compared with rates obtained from food-deprived fish.
  • Patterns of J(urea) were free running with a 24 h period under conditions of continuous darkness (0:24 L:D).
  • The results of this study show that J(urea) in R. marmoratus demonstrates the characteristics of a circadian rhythm: a 24 h periodicity, a free-running rhythm in continuous conditions, and entrainment to new photoperiods.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. UREA .
  • Hazardous Substances Data Bank. Ammonia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809460.001).
  • [ISSN] 0022-0949
  • [Journal-full-title] The Journal of experimental biology
  • [ISO-abbreviation] J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 7664-41-7 / Ammonia; 8W8T17847W / Urea
  •  go-up   go-down


3. Douet-Guilbert N, Andrieux J, Laï JL, Morice P, Demory JL, Basinko A, Ugo V, Gueganic N, Le Bris MJ, Morel F, De Braekeleer M: Isoderivative of deleted chromosome 20 in primary myelofibrosis (PMF) characterized by molecular cytogenetics and array CGH. Ann Hematol; 2009 Nov;88(11):1157-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isoderivative of deleted chromosome 20 in primary myelofibrosis (PMF) characterized by molecular cytogenetics and array CGH.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 20 / genetics. Comparative Genomic Hybridization / methods. Isochromosomes / genetics. Primary Myelofibrosis / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444446.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


Advertisement
4. Harada H, Harada Y, Kimura A: [Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes]. Nihon Rinsho; 2009 Oct;67(10):1901-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular mechanisms in myeloproliferative diseases and myelodysplastic syndromes].
  • Little was known about the mechanisms for myeloproliferative diseases (MPD) until 2005 when an activating mutation in the JAK2 tyrosine kinase (JAK2 V617F) was identified in >95% of patients with polycythemia vera (PV), and in a significant proportion of patients with essential thormbocythemia (ET) and primary myelofibrosis (PMF).
  • [MeSH-major] Myelodysplastic Syndromes / genetics. Myeloproliferative Disorders / genetics


5. Shaheen SP 2nd, Talwalkar SS, Simons R, Yam L: Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature. Arch Pathol Lab Med; 2005 Jan;129(1):96-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature.
  • Leukemic transformation of chronic idiopathic myelofibrosis (CIMF) to acute lymphoblastic leukemia (ALL) is rare.
  • We report a case of a patient with CIMF who developed paroxysmal nocturnal hemoglobinuria (PNH) 2 years after initial presentation.
  • His disease eventually transformed to ALL of precursor B-cell type.
  • In that CIMF and PNH are clonal stem cell disorders with different pathogeneses, there may be an association between them.
  • However, leukemic transformation is a rare sequel of both disorders.
  • Coexistence of CIMF and PNH and subsequent transformation to ALL have, to our knowledge, never been previously reported in the world literature.
  • The simultaneous presentation of CIMF and PNH, complicated by the rare sequela of leukemic transformation, raises important issues with regard to diagnosis and treatment.
  • [MeSH-major] Hemoglobinuria, Paroxysmal / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Primary Myelofibrosis / complications
  • [MeSH-minor] Chronic Disease. Humans. Male. Middle Aged


6. Levine RL, Pardanani A, Tefferi A, Gilliland DG: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer; 2007 Sep;7(9):673-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
  • The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors.
  • These discoveries have changed the landscape for diagnosis and classification of PV, ET and PMF, and show the ability of genomic technologies to identify new molecular targets in human malignancies with pathogenetic, diagnostic and therapeutic significance.
  • [MeSH-major] Janus Kinase 2 / genetics. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721432.001).
  • [ISSN] 1474-175X
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 114
  •  go-up   go-down


7. Dedachi KI, Natsume T, Nakatsu T, Tanaka S, Ishikawa Y, Kurita N: Charge Transfer Through Single- and Double-strand DNAs: Simulations Based on Molecular Dynamics and Molecular Orbital Methods. Chem Phys Lett; 2007 Feb 27;436(1-3):244-251
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stable structures of DNA strands in water were determined by MD simulations and their energy levels and distributions of frontier MOs that mediate charge transfer were analyzed by the MO calculations.
  • The transfer integrals for a hole or an electron between the neighboring DNA bases were estimated from the energy levels of frontier MOs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587841.001).
  • [ISSN] 0009-2614
  • [Journal-full-title] Chemical physics letters
  • [ISO-abbreviation] Chem Phys Lett
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM008102-350088; United States / NIGMS NIH HHS / GM / S06 GM008102
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Kaya H, Cerci SS: Tc-99m nanocolloid scintigraphic imaging of intracranial meningeal extramedullary hematopoiesis in a patient with idiopathic myelofibrosis. Ann Nucl Med; 2006 Oct;20(8):565-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tc-99m nanocolloid scintigraphic imaging of intracranial meningeal extramedullary hematopoiesis in a patient with idiopathic myelofibrosis.
  • Meningeal extramedullary hematopoiesis (EMH) is a rare finding in idiopathic myelofibrosis.
  • Diagnosis of EMH is difficult, based on clinical circumstances and the use of different diagnostic imaging modalities, such as CT, MRI or radionuclide imaging.
  • We present a case with intracranial medullary hematopoiesis due to idiopathic myelofibrosis diagnosed with Tc-99m nanocolloid scintigraphy.
  • In Tc-99m MDP bone scintigraphy, increased osteoblastic activity in the left frontal and parietal bones, in shoulders, knee and ankle joints, and in both metatarsal bones were seen.
  • A biopsy of the mass revealed extramedullary hematopoiesis composed of erythroblasts, mature and immature myeloid cells, and megakaryocytes.
  • [MeSH-major] Brain Diseases / diagnosis. Hematopoiesis, Extramedullary. Primary Myelofibrosis / complications. Radionuclide Imaging / methods. Radiopharmaceuticals / pharmacology. Technetium Tc 99m Aggregated Albumin / pharmacology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Nuclear Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134026.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


9. Verhoeven JJ, Brand JB, van de Polder MM, Joosten KF: Management of hyperglycemia in the pediatric intensive care unit; implementation of a glucose control protocol. Pediatr Crit Care Med; 2009 Nov;10(6):648-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of hyperglycemia in the pediatric intensive care unit; implementation of a glucose control protocol.
  • Fifty children (28 boys), aged 3.5 yrs (range, 1.2 -9.3 yrs) were treated in 18 mos.
  • CONCLUSION: The use of a stepwise nurse-driven glucose control protocol resulted in normoglycemia within 12 hrs for 94% of the children involved.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Hyperglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Crit Care Med. 2010 Jan;11(1):163 [20051803.001]
  • (PMID = 19602994.001).
  • [ISSN] 1529-7535
  • [Journal-full-title] Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
  • [ISO-abbreviation] Pediatr Crit Care Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hypoglycemic Agents; 0 / Insulin
  •  go-up   go-down


10. Tsao AK, Smaldone MD, Averch TD, Jackman SV: Robot-assisted laparoscopic prostatectomy: the first 100 patients-improving patient safety and outcomes. J Endourol; 2009 Mar;23(3):481-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report our initial experience of 100 patients with robot-assisted laparoscopic prostatectomy (RALP) with a focus on patient safety and outcomes.
  • RESULTS: Mean age was 59.4 years (range 44.5-72.6 yrs), body mass index was 28.4 (range 20.4-40.1), preoperative prostate-specific antigen (PSA) level was 5.7 ng/mL (range 0.4-15.0 ng/mL), and follow-up was 12.7 months (range 7 days-38 mos).
  • Twelve patients had pT(2a) disease, 3 had T(2b), 61 had T(2c), 22 had T(3a)N(0), and 1 had T(3b)N(1).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245295.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Altmannshofer S, Herdtweck E, Köhler FH, Miller R, Mölle R, Scheidt EW, Scherer W, Train C: Crystal-packing-induced antiferromagnetic interactions of metallocenes: cyanonickelocenes, -cobaltocenes, and -ferrocenes. Chemistry; 2008;14(26):8013-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cyano-substituted metallocenes [M(C5H4CN)2] (M=Fe, 1; Co, 2; Ni 3) and [M(C5Me5)(C5H4CN)] (M=Fe, 4; Co, 5; Ni, 6) were synthesized in yields up to 58 % by treating K(C5H4CN) or Tl(C5H4CN) with suitable transition-metal precursors.
  • These results pointed to antiferromagnetic interactions as a consequence of molecular ordering in the lattice, as confirmed by magnetic measurements.
  • The magnetic interaction was interpreted as a Heitler-London spin exchange and was analyzed based on how the interaction depends on the singly occupied MOs and the shift of parallel metallocenes relative to each other.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18645991.001).
  • [ISSN] 0947-6539
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Daly JJ, Sng K, Roenigk K, Fredrickson E, Dohring M: Intra-limb coordination deficit in stroke survivors and response to treatment. Gait Posture; 2007 Mar;25(3):412-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Five healthy controls and 32 chronic (>12 mos) stroke survivors were enrolled, and H/K ACC was calculated for both groups.

  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • MedlinePlus Health Information. consumer health - Walking Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16824762.001).
  • [ISSN] 0966-6362
  • [Journal-full-title] Gait & posture
  • [ISO-abbreviation] Gait Posture
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


13. Stembalska A, Barg E, Jakiel A, Sasiadek MM: [Familial chromosome X structural aberrations - case report]. Pediatr Endocrinol Diabetes Metab; 2010;16(4):310-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In one of the cases (family A) a mother with a mosaic X chromosome aberration [mos 45,X/46,X,der(X)(qter→q2?
  • 7::p22.2→qter)], with previously undiagnosed Turner's syndrome, gave birth to her third daughter with a karyotype that contained only the structural X chromosome aberration, of maternal origin [46,X,der(X)(qter→q2?
  • In the second case (family B) a mother [46,X,del(X)(p22.1p22.2).ish del(X)(wcpX+, pter+, KAL-, qter+)] gave birth to a girl with Down syndrome (21 trisomy), who has also had an additional chromosome X aberration [47,X,del(X)(p22.1p22.2),+21.ish del(X)(wcpX+, pter+, KAL-, qter+)].
  • In such cases, the diagnosis usually occurs incidentally.

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21447275.001).
  • [ISSN] 2081-237X
  • [Journal-full-title] Pediatric endocrinology, diabetes, and metabolism
  • [ISO-abbreviation] Pediatr Endocrinol Diabetes Metab
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Mues AC, Palacios JM, Haramis G, Casazza C, Badani K, Gupta M, McKiernan J, Benson MC, Landman J: Contemporary experience in the management of angiomyolipoma. J Endourol; 2010 Nov;24(11):1883-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: A prospectively evaluated database was reviewed, and we identified 91 patients with the diagnosis of renal AML who presented between June 1985 and February 2009.
  • After a median follow-up of 54.8 months (range 0.2-211.7 mos), there was a mean growth rate of 0.088 cm/year in the group who were treated with AS.
  • AS for AMLs is associated with a slow and consistent growth rate (0.088 cm/year), typically has minimal morbidity, and is a reasonable option in selected patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20919915.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Uzbekova S, Arlot-Bonnemains Y, Dupont J, Dalbiès-Tran R, Papillier P, Pennetier S, Thélie A, Perreau C, Mermillod P, Prigent C, Uzbekov R: Spatio-temporal expression patterns of aurora kinases a, B, and C and cytoplasmic polyadenylation-element-binding protein in bovine oocytes during meiotic maturation. Biol Reprod; 2008 Feb;78(2):218-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maturation of immature bovine oocytes requires cytoplasmic polyadenylation and synthesis of a number of proteins involved in meiotic progression and metaphase-II arrest.
  • In frog and mouse oocytes, Aurora A regulates polyadenylation-dependent translation of several mRNAs such as MOS and CCNB1, presumably by phosphorylating CPEB, and Aurora B phosphorylates histone H3 during meiosis.
  • [MeSH-minor] Animals. Aurora Kinase A. Aurora Kinase B. Aurora Kinase C. Aurora Kinases. Butadienes / pharmacology. CDC2 Protein Kinase / analysis. CDC2 Protein Kinase / genetics. CDC2 Protein Kinase / metabolism. Cattle. Cyclin B / analysis. Cyclin B / genetics. Cyclin B / metabolism. Cyclin B1. Cytoplasm / chemistry. Cytoplasm / metabolism. Embryo, Mammalian / metabolism. Female. Fertilization. Metformin / pharmacology. Nitriles / pharmacology. Piperazines / pharmacology. Polyadenylation. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-mos / analysis. Proto-Oncogene Proteins c-mos / genetics. Proto-Oncogene Proteins c-mos / metabolism. Purines / pharmacology. RNA, Messenger / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687118.001).
  • [ISSN] 0006-3363
  • [Journal-full-title] Biology of reproduction
  • [ISO-abbreviation] Biol. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Butadienes; 0 / Ccnb1 protein, mouse; 0 / Cyclin B; 0 / Cyclin B1; 0 / Nitriles; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Purines; 0 / RNA, Messenger; 0 / U 0126; 0 / mRNA Cleavage and Polyadenylation Factors; 0 / roscovitine; 639089-54-6 / VX680; 9100L32L2N / Metformin; EC 2.7.11.1 / Aurka protein, mouse; EC 2.7.11.1 / Aurkb protein, mouse; EC 2.7.11.1 / Aurkc protein, mouse; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinase C; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-mos; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


16. Glass IA, Rauen KA, Chen E, Parkes J, Alberston DG, Pinkel D, Cotter PD: Ring chromosome 15: characterization by array CGH. Hum Genet; 2006 Jan;118(5):611-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ring chromosome 15 [r(15)] is an uncommon finding with less than 50 patients reported.
  • We report two discordant examples of r(15) patients.
  • In the first case, prenatal diagnosis of a de novo r(15) was made during the second trimester: mos 46,XX,r(15)(p11.2q26)[32]/45,XX,-15[13]/47,XX,r(15)(p11.2q26)x2[3]/46,XX,dic r(15)(p11.2q26p11.2q26[1]/46,XX[2].
  • [MeSH-minor] Adult. Chromosome Aberrations. Female. Genotype. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Phenotype. Pregnancy. Prenatal Diagnosis

  • Genetic Alliance. consumer health - Chromosome 15 Ring.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Am J Hum Genet. 1995 Nov;57(5):1137-42 [7485165.001]
  • [Cites] Hum Genet. 1991 Jul;87(3):320-4 [1864607.001]
  • [Cites] Am J Med Genet. 1996 Mar 1;62(1):10-5 [8779316.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1037-49 [10215630.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1303-9 [12379849.001]
  • [Cites] Clin Dysmorphol. 1993 Apr;2(2):106-13 [7506614.001]
  • [Cites] Hum Genet. 1993 Aug;92(1):23-7 [8365723.001]
  • [Cites] Hum Genet. 1987 Feb;75(2):174-9 [3817812.001]
  • [Cites] Ann Genet. 1986;29(1):45-8 [3487276.001]
  • [Cites] Genome Res. 2002 Feb;12(2):325-32 [11827952.001]
  • [Cites] Hum Genet. 1990 Jun;85(1):138-9 [2358298.001]
  • [Cites] Am J Med Genet. 1988 Jan;29(1):149-54 [3278612.001]
  • [Cites] Clin Genet. 1992 Apr;41(4):178-80 [1576754.001]
  • [Cites] Science. 2004 Jul 23;305(5683):525-8 [15273396.001]
  • [Cites] J Med Genet. 1995 Jun;32(6):486-7 [7545237.001]
  • [Cites] Cytogenet Cell Genet. 1995;70(3-4):228-34 [7789178.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Am J Med Genet. 1991 Jan;38(1):74-9 [1849352.001]
  • [Cites] Cell. 2001 Feb 23;104(4):557-67 [11239412.001]
  • [Cites] Am J Med Genet A. 2004 Nov 1;130A(4):340-4 [15384084.001]
  • [Cites] Eur J Hum Genet. 1997 Jul-Aug;5(4):235-41 [9359045.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):249-60 [11443548.001]
  • [Cites] Am J Med Genet A. 2004 Apr 15;126A(2):183-5 [15057983.001]
  • [Cites] Am J Med Genet. 1991 Sep 15;40(4):460-3 [1746611.001]
  • [Cites] J Med Genet. 1985 Jun;22(3):233-6 [4040173.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Nov;51(5):541-50 [10594514.001]
  • [Cites] Am J Med Genet. 2002 Jun 1;110(1):51-6 [12116271.001]
  • [Cites] Clin Genet. 2002 Nov;62(5):415-7 [12431259.001]
  • (PMID = 16267671.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83040; United States / NCI NIH HHS / CA / CA84118; United States / NICHD NIH HHS / HD / HD048502
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  •  go-up   go-down


17. Morgan KJ, Gilliland DG: A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med; 2008;59:213-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for JAK2 mutations in myeloproliferative diseases.
  • Myeloproliferative disorders (MPDs) are characterized by a clonal expansion of myeloid cells.
  • Over the past two years, the identification of the JAK2V617F mutation in most cases of polycythemia vera (PV) as well as approximately 50% of patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) has greatly advanced our understanding of MPDs.
  • Regardless of the various pathologies, the JAK2V617F discovery highlights the importance of JAK-STAT signaling in myeloid differentiation and focuses effort on developing a clinically relevant JAK2 inhibitor.
  • [MeSH-major] Janus Kinase 2 / genetics. Mutation / genetics. Myeloproliferative Disorders / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919086.001).
  • [ISSN] 0066-4219
  • [Journal-full-title] Annual review of medicine
  • [ISO-abbreviation] Annu. Rev. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT Transcription Factors; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 38
  •  go-up   go-down


18. Pancrazzi A, Guglielmelli P, Ponziani V, Bergamaschi G, Bosi A, Barosi G, Vannucchi AM: A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn; 2008 Sep;10(5):435-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.
  • Acquired mutations in the juxtamembrane region of MPL (W515K or W515L), the receptor for thrombopoietin, have been described in patients with primary myelofibrosis or essential thrombocythemia, which are chronic myeloproliferative disorders.
  • None of the 60 control subjects presented with a MPLW515L/K mutation.
  • Of 217 patients with myelofibrosis, 19 (8.7%) harbored the MPLW515 mutation, 10 (52.6%) with the W515L allele.
  • This is a simple, sensitive, and cost-effective procedure for large-scale screening of the MPLW515L/K mutation in patients suspected to have a myeloproliferative disorder.
  • [MeSH-major] DNA Probes / chemistry. Mutation. Myeloproliferative Disorders / genetics. Oligonucleotides / chemistry. Receptors, Thrombopoietin / genetics
  • [MeSH-minor] Alleles. Case-Control Studies. Chronic Disease. Genetic Testing / economics. Humans. Janus Kinase 2 / genetics. Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Exp Hematol. 2007 Jan;35(1):32-8 [17198871.001]
  • [Cites] Mol Cell Probes. 2003 Oct;17(5):253-9 [14580400.001]
  • [Cites] Blood. 1996 Jul 15;88(2):402-9 [8695786.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4369-83 [9373248.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1847-9 [16079890.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3339-47 [16322778.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):631-5 [16369984.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1864-71 [16249382.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3472-6 [16868251.001]
  • [Cites] PLoS Med. 2006 Jul;3(7):e270 [16834459.001]
  • [Cites] Br J Haematol. 2006 Dec;135(5):683-7 [17107350.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1241-3 [17023581.001]
  • [Cites] N Engl J Med. 2007 Feb 1;356(5):459-68 [17267906.001]
  • [Cites] Br J Haematol. 2007 May;137(3):244-7 [17408465.001]
  • [Cites] Br J Haematol. 2007 May;137(4):378-9 [17408398.001]
  • [Cites] Leukemia. 2007 May;21(5):1128-30 [17301814.001]
  • [Cites] Blood. 2007 Aug 1;110(3):840-6 [17379742.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1092-7 [17488875.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1411-9 [17435115.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1952-9 [17625606.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2206-7 [17507998.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3735-43 [17709604.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4030-6 [17712047.001]
  • [Cites] Leukemia. 2008 Jan;22(1):23-30 [17882282.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1299-307 [18496562.001]
  • [Cites] Blood. 2008 Aug 1;112(3):844-7 [18519816.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1316-21 [17018857.001]
  • [Cites] Exp Hematol. 2002 Mar;30(3):229-36 [11882360.001]
  • [Cites] Haematologica. 2006 Dec;91(12 Suppl):ECR57 [17194663.001]
  • [Cites] Hum Mutat. 2003 Jul;22(1):79-85 [12815597.001]
  • (PMID = 18669880.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / Oligonucleotides; 0 / Receptors, Thrombopoietin; 0 / locked nucleic acid; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC2518738
  •  go-up   go-down


19. Hidaka T, Shide K, Shimoda H, Kameda T, Toyama K, Katayose K, Kubuki Y, Nagata K, Takenaka K, Akashi K, Okamura T, Niho Y, Mizoguchi H, Omine M, Ozawa K, Harada M, Shimoda K: The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. Eur J Haematol; 2009 Oct;83(4):328-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
  • Cytogenetic abnormalities were often observed in primary myelofibrosis patients.
  • The presence of specific cytogenetic abnormalities, such as sole abnormalities of chromosome 13q-, 20q-, or -7/7q-, is reported to have the influence on the prognosis of primary myelofibrosis.
  • We analyzed the data from the prospective survey of Japanese primary myelofibrosis patients which was conducted from 1999 to clarify the impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis.
  • A total of 202 primary myelofibrosis patients had the cytogenetic and the prognostic data.
  • Although the presence of an abnormal karyotype did not affect the prognosis, primary myelofibrosis patients with cytogenetic abnormalities other than 13q- and 20q- showed an inferior prognosis compared to patients with a normal karyotype or sole 13q- or 20q- abnormalities.
  • Patients with an unfavorable cytogenetic profile (abnormal cytogenetics other than 13q- or 20q-) also had a greater tendency to transform to leukemia than patients with a favorable cytogenetic profile (normal cytogenetics, sole abnormalities of either chromosome 13q-, or 20q-).
  • Abnormal cytogenetics other than 13q- or 20q- in primary myelofibrosis patients has the poor prognostic effect for both survival and the risk of leukemic transformation.
  • [MeSH-major] Chromosome Aberrations. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2009 Oct;83(4):290-1 [19558507.001]
  • (PMID = 19549278.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


20. Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST, OPTIMA Team1: Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr; 2009 Aug 15;51(5):631-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.
  • OBJECTIVE: To investigate the relative magnitude and duration of impact of AIDS-defining events (ADEs) and non-AIDS serious adverse events (SAEs) on health-related quality of life (HRQoL) among patients with advanced HIV/AIDS.
  • METHODS: We use data from OPTIMA (OPTions In Management with Antiretrovirals), a multinational, randomized, open, control, clinical management trial of treatment strategies for patients with multidrug-resistant HIV and advanced immune disease.
  • The Medical Outcomes Study HIV Health Survey (MOS-HIV) physical and mental health summary scores (MOS-PHS and MOS-MHS), EQ-5D, and the Health Utilities Index Mark 3 HRQoL measures were all assessed at regular follow-up intervals during the trial.
  • CONCLUSIONS: Non-AIDS SAEs occurring in patients with late-stage HIV/AIDS seem to have at least as important an immediate impact on patient HRQoL as ADEs; however, the impact of ADEs seems to be more persistent.
  • Our findings call for a greater emphasis on the detection and active prevention of non-AIDS SAEs in patients with late-stage HIV/AIDS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Living with HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430303.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Investigator] Schechter M; Deyton LR; Darbyshire J; Brown S; Holodniy M; Kyriakides TC; Owens D; Yu W; Cameron W; Singer J; Anis AH; Gazzard B; Youle M; Hooker M; Babiker A; Sculpher M; Breckenridge A; Volberding P; Wainberg M; Schulman K; McIver D; Collins S; Atkinson M; Peduzzi P; Schmid I; McClaren A; Farewell V; Foulkes MA; Cotton D; Laupacis A
  •  go-up   go-down


21. Sun S, Tang W, Song F, Yu T, Ristagno G, Shan Y, Weng Y, Weil MH: The effects of epinephrine on outcomes of normothermic and therapeutic hypothermic cardiopulmonary resuscitation. Crit Care Med; 2010 Nov;38(11):2175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEASUREMENTS AND MAIN RESULTS: Postresuscitation cardiac output, ejection fraction, and myocardial performance index were measured hourly for 4 hrs after resuscitation; neurologic deficit scores were measured daily for 7 days, and durations of survival were observed for up to 3 mos.

  • MedlinePlus Health Information. consumer health - CPR.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2010 Nov;38(11):2264-5 [20959758.001]
  • (PMID = 20693888.001).
  • [ISSN] 1530-0293
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] YKH834O4BH / Epinephrine
  •  go-up   go-down


22. Sullivan K, Klassen T, Mulroy S: Combined task-specific training and strengthening effects on locomotor recovery post-stroke: a case study. J Neurol Phys Ther; 2006 Sep;30(3):130-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intent of this case study is to describe outcomes associated with a therapy program that combines task-specific and strength training in an individual post-stroke and to discuss some possible mechanisms and modulating factors that may affect post-stroke neurologic recovery and responsiveness to intervention.
  • Body-weight supported treadmill training and a limb-loaded cycling exercise were alternated over 24 treatments sessions (4 times/wk for 6 wks).
  • At 6-mos, continued improvements in all walking outcomes were evident.
  • DISCUSSION: For the person in this case clinically meaningful changes in walking function were associated with a combined therapeutic program that included both task-specific and LE strength training.

  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • MedlinePlus Health Information. consumer health - Walking Problems.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17029656.001).
  • [ISSN] 1557-0576
  • [Journal-full-title] Journal of neurologic physical therapy : JNPT
  • [ISO-abbreviation] J Neurol Phys Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Hashimoto H, Komagata M, Nakai O, Morishita M, Tokuhashi Y, Sano S, Nohara Y, Okajima Y: Discriminative validity and responsiveness of the Oswestry Disability Index among Japanese outpatients with lumbar conditions. Eur Spine J; 2006 Nov;15(11):1645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recruited 167 outpatients from seven participating clinics, and concurrently measured the translated ODI and MOS Short Form 36 (SF36) as a reference scale.
  • [MeSH-major] Disability Evaluation. Low Back Pain / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Spine J. 2006 Nov;15(11):1651 [16477451.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Jul 15;28(14):1601-7 [12865852.001]
  • [Cites] Scand J Rheumatol. 1995;24(2):61-3 [7747144.001]
  • [Cites] J Chronic Dis. 1986;39(11):897-906 [2947907.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jan;79(1):48-52 [9020444.001]
  • [Cites] Pain. 1996 Apr;65(1):71-6 [8826492.001]
  • [Cites] Control Clin Trials. 1991 Aug;12(4 Suppl):142S-158S [1663851.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Mar 15;28(6):607-15 [12642770.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Feb 15;28(4):317-23 [12590203.001]
  • [Cites] Spine (Phila Pa 1976). 2005 Mar 1;30(5):E123-7 [15738775.001]
  • [Cites] Spine (Phila Pa 1976). 2005 Apr 15;30(8):857-62 [15834326.001]
  • [Cites] Eur Spine J. 2005 Nov;14 (9):828-32 [15864666.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Nov 15;25(22):2940-52; discussion 2952 [11074683.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):1037-44 [9817121.001]
  • [Cites] Spine (Phila Pa 1976). 2002 Aug 15;27(16):1797-801 [12195074.001]
  • [Cites] Stat Med. 1985 Jan-Mar;4(1):87-90 [3992076.001]
  • [Cites] Eur Spine J. 2006 Jan;15(1):55-65 [15856341.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Jan 1;22(1):68-71 [9122784.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Mar 1;29(5):581-5; discussion 585 [15129077.001]
  • [Cites] Clin Orthop Relat Res. 2003 Jun;(411):40-53 [12782858.001]
  • [Cites] Eur Spine J. 2004 Feb;13(1):14-21 [14658061.001]
  • [Cites] Phys Ther. 2002 Jan;82(1):8-24 [11784274.001]
  • [Cites] J Clin Epidemiol. 1989;42(5):403-8 [2659745.001]
  • [Cites] Eur Spine J. 2006 Jan;15(1):66-73 [15856340.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Dec 15;25(24):3115-24 [11124727.001]
  • [Cites] J Bone Joint Surg Br. 2005 Mar;87(3):352-5 [15773645.001]
  • [Cites] J Clin Epidemiol. 1998 Nov;51(11):1045-53 [9817122.001]
  • [Cites] Spine (Phila Pa 1976). 1995 Jul 1;20(13):1535-7 [8623078.001]
  • [Cites] Eur Spine J. 2004 Jul;13(4):325-9 [14714243.001]
  • (PMID = 16477452.001).
  • [ISSN] 0940-6719
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


24. Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L, Palermo S, Vittadello F, Pycha A: uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer; 2006 Feb 25;108(1):60-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The authors provide an update on the clinical value and role of the uCyt+/ImmunoCyt test as a noninvasive tool for the detection of recurrent urothelial carcinoma.
  • These patients mostly had been followed for superficial urothelial carcinoma (UC) confined to the mucosa and lamina propria (pathologic tumor [pT] classification pTa, pT1, and pTis [carcinoma in situ]) for a mean of 15.62 months (range, 4-28 mos).
  • Used as a noninvasive tool, cytology escorted by uCyt+/ImmunoCyt may reduce the morbidity and cost of follow-up for patients who have a low risk of recurrence while avoiding superfluous cystoscopic examinations.
  • [MeSH-major] Antibodies, Monoclonal. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16411183.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm
  •  go-up   go-down


25. Gozzetti A, Crupi R, Tozzuoli D, Fabbri A, Bocchia M, Lauria F: Trisomy 13 in a patient with idiopathic myelofibrosis. Cancer Genet Cytogenet; 2005 Jan 15;156(2):185
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trisomy 13 in a patient with idiopathic myelofibrosis.
  • [MeSH-major] Chromosomes, Human, Pair 13. Primary Myelofibrosis / genetics. Trisomy

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Trisomy 13.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642403.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


26. Hillengass J, Zechmann C, Bäuerle T, Wagner-Gund B, Heiss C, Benner A, Ho A, Neben K, Hose D, Kauczor HU, Goldschmidt H, Delorme S, Moehler T: Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res; 2009 May 1;15(9):3118-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation.
  • PURPOSE: The aim of our study was to investigate whether dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) allows visualization of changes in microcirculation between healthy controls on the one side and early/advanced stages of plasma cell disease on the other.
  • EXPERIMENTAL DESIGN: We examined a group of 222 individuals consisting of 60 patients with monoclonal gammopathy of undetermined significance (MGUS), 65 patients with asymptomatic multiple myeloma (aMM), 75 patients with newly diagnosed symptomatic MM (sMM), and 22 healthy controls with DCE-MRI of the lumbar spine.
  • RESULTS: A continuous increase in microcirculation parameters amplitude A and exchange rate constant kep reflecting vascular volume and permeability, respectively, was detected from normal controls over MGUS and aMM to sMM.
  • For A and kep, significant differences were found between controls and aMM (P = 0.03 and P = 0.004, respectively) as well as controls and sMM (P = 0.001 and P < 0.001, respectively).
  • Although diffuse microcirculation patterns were found in healthy controls as well as MGUS and MM, a pattern with focal hotspots was exclusively detected in 42.6% of sMM and in 3 MGUS and 3 aMM patients.
  • MGUS and aMM patients with increased microcirculation patterns showed significantly higher bone marrow plasmocytosis compared with patients with a low microcirculation pattern.
  • Pathologic DCE-MRI findings correlate with adverse prognostic factors and DCE-MRI identifies a distinct group of patients with increased microcirculation parameters in aMM and MGUS patients.
  • [MeSH-major] Bone Marrow / blood supply. Contrast Media. Magnetic Resonance Imaging. Multiple Myeloma / diagnosis. Paraproteinemias / diagnosis. Plasma Cells / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19366830.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


27. Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, Pecci A, Viarengo G, Meli V, Marchetti M, Guglielmelli P, Bruno E, Xu M, Hoffman R, Barosi G, Italian Registry of Myelofibrosis with Myeloid Metaplasia, Myeloproliferative Disorders Research Consortium: The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis; 2007 May-Jun;38(3):280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.
  • PURPOSE: We studied the expression of the chemokine receptor CXCR4 on circulating CD34+ cells of patients with myelofibrosis with myeloid metaplasia (MMM), and examined its relationship to the severity of disease.
  • CXCR4 expression on CD34+ cells inversely correlated with the number of circulating CD34+ cells (R=-0.55; P<0.001), and was severely down-regulated in high risk patients and patients with a high "myelodepletion severity index".
  • CXCR4 down-regulation was associated with advanced patient age, the presence of severe anemia, thrombocytopenia, and degree of bone marrow fibrosis.
  • CONCLUSIONS: Reduced expression of CXCR4 by CD34+ cells is a characteristic of MMM which is associated with the constitutive mobilization of CD34+ cells and occurs in patients with advanced forms of the disease.
  • [MeSH-major] Primary Myelofibrosis / blood. Receptors, CXCR4 / metabolism

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350297.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 108671-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers; 0 / RNA, Messenger; 0 / Receptors, CXCR4
  •  go-up   go-down


28. Bensouda-Grimaldi L, Jonville-Béra AP, Mouret E, Elefant E, Dhellot H, Delmas C, Gouin T, Coste P, Autret-Leca E, les Centres Régionaux de Pharmacovigilance: [Isotretinoin: compliance with recommendations in childbearing women]. Ann Dermatol Venereol; 2005 May;132(5):415-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Isotrétinoïne: suivi de l'application des recommandations des prescriptions chez les femmes en âge de procréer.
  • INTRODUCTION: The aim of this survey is to ascertain if the incidence of isotretinoin exposed pregnancies was reduced by the late recommendations of prescription and issue (AMM modification on 06/08/2001 and 25/09/2001).
  • The reason of the 22 lacking contraception was known 12 times, i.e. an absence of prescription (6 times), a refusal to take a prescribed contraception (3 times) and a self-medication (3 times).
  • Incidence of isotretinoin exposed pregnancies remained stable, 0.26/1000 treated women (vs 0.34 after 2001's AMM modifications).
  • At last, only 6 patients (9 p. 100) have both a correctly written prescription, a contraception and a time between the pregnancy test date and prescription and issue dates, in accordance with the licence and have had a correct information and understood it.
  • However, this study does not allow to assess the proportion of issued prescriptions despite their non-accordance with the licence criteria.

  • MedlinePlus Health Information. consumer health - Pregnancy.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988352.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contraceptive Agents; EH28UP18IF / Isotretinoin
  •  go-up   go-down


29. Periard D, Currat M, Qanadli SD, Hayoz D, Vollenweider P: Myelofibrosis and spinal cord ischaemia. Thromb Haemost; 2009 Mar;101(3):584-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelofibrosis and spinal cord ischaemia.
  • [MeSH-major] Primary Myelofibrosis / complications. Spinal Cord Ischemia / complications
  • [MeSH-minor] Aged. Chronic Disease. Female. Humans

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277425.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Wulfert M, Küpper AC, Tapprich C, Bottomley SS, Bowen D, Germing U, Haas R, Gattermann N: Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol; 2008 May;36(5):577-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the frequency and spectrum of somatic mutations of mitochondrial DNA (mtDNA) in bone marrow of patients with myelodysplastic syndrome (MDS).
  • MATERIALS AND METHODS: Analysis included 104 patients with MDS (24 refractory anemia, 32 refractory anemia with ringed sideroblasts, 34 refractory anemia with excess of blasts, 7 refractory anemia with excess of blasts in transformation to acute leukemia, and 7 chronic myelo-monocytic leukemia), 3 patients with acute myeloid leukemia from MDS, and 36 patients with myeloproliferative disease (23 chronic myeloid leukemia, 9 polycythemia vera, 4 idiopathic myelofibrosis).
  • RESULTS: Heteroplasmic mtDNA mutations, mostly transitions, were identified in 56% of MDS and 44% of myeloproliferative disorders patients.
  • In MDS, mutation frequency increased with age and more-advanced disease.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Bone Marrow / pathology. Chromatography, High Pressure Liquid / methods. DNA Mutational Analysis. Disease Progression. Humans. Middle Aged. Mutation. Polymerase Chain Reaction / methods. Sensitivity and Specificity


31. Shi Y, Xu C: Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases. Recent Pat DNA Gene Seq; 2008;2(3):209-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
  • Recent studies have found that JAK2V617F mutation is present in approximately 90-95% of patients with polycythemia vera (PV), and also in approximately half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
  • The discovery of these molecular markers has not only greatly improved the diagnosis of these chronic myeloproliferative diseases, but also evoked considerable enthusiasm for the development of specific therapies targeted at those mutant genes and their product.
  • [MeSH-major] Janus Kinase 2 / metabolism. Myeloproliferative Disorders / genetics. Patents as Topic. STAT Transcription Factors / metabolism
  • [MeSH-minor] Humans. Mutation. Polycythemia Vera / diagnosis. Polycythemia Vera / genetics. Polycythemia Vera / metabolism. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / genetics. Primary Myelofibrosis / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19075958.001).
  • [ISSN] 2212-3431
  • [Journal-full-title] Recent patents on DNA & gene sequences
  • [ISO-abbreviation] Recent Pat DNA Gene Seq
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / STAT Transcription Factors; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 34
  •  go-up   go-down


32. Bertakis KD, Azari R: Patient gender differences in the prediction of medical expenditures. J Womens Health (Larchmt); 2010 Oct;19(10):1925-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Before their first primary care visit, 509 new patients were interviewed.
  • Data collected included sociodemographics, self-reported health status Medical Outcomes Study Short-Form (MOS SF-36), body mass index (BMI), and screening for alcoholism and smoking.
  • Lower physical health status was associated with higher charges for primary care (p = 0.0022), specialty care (p = 0.0141), diagnostic services (p < 0.0001), hospitalizations (p = 0.0069), and total charges (p < 0.0001).
  • Female patients had higher charges for primary care (p = 0.0019), diagnostic services (p = 0.0005), and total charges (p = 0.0180).
  • [MeSH-major] Health Expenditures. Health Status Indicators. Primary Health Care / utilization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20831429.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R18 HS06167
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


33. Yohannan J, Feng T, Berkowitz J, Connolly SS, Pierorazio P, Allaf ME: Laparoscopic resection of local recurrence after previous radical nephrectomy for clinically localized renal-cell carcinoma: perioperative outcomes and initial observations. J Endourol; 2010 Oct;24(10):1609-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean age of patients was 57 years (44-66 y), all had primary tumors with clear-cell histology, and Eastern Cooperative Oncology Group performance status was 0.
  • At a mean follow-up of 12 months (2-26 mos), 1 patient experienced further recurrence.
  • All patients are alive, and three have no evidence of disease.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Endourol. 2011 Apr;25(4):705 [21417749.001]
  • (PMID = 20629564.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Mithraprabhu S, Grigoriadis G, Khong T, Spencer A: Deactylase inhibition in myeloproliferative neoplasms. Invest New Drugs; 2010 Dec;28 Suppl 1:S50-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deactylase inhibition in myeloproliferative neoplasms.
  • Myeloproliferative neoplasms (MPN) are clonal haemopoietic progenitor cell disorders characterized by the proliferation of one or more of the haemopoietic lineages (myeloid, erythroid and/or megakaryocytic).
  • The MPNs include eight haematological disorders: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), systemic mastocytosis (SM), chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), chronic neutrophilic leukemia (CNL), and unclassifiable MPN (MPN, U).
  • Histone deacetylase inhibitors (HDACi) are a novel class of drugs capable of altering the acetylation status of both histone and non-histone proteins, thereby affecting a repertoire of cellular functions in neoplastic cells including proliferation, differentiation, immune responses, angiogenesis and survival.
  • [MeSH-major] Histone Deacetylase Inhibitors / therapeutic use. Histone Deacetylases / metabolism. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / enzymology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 2003 Nov 20;46(24):5097-116 [14613312.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):672-7 [14744784.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):627-38 [15023334.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34227-39 [15175350.001]
  • [Cites] Expert Opin Investig Drugs. 2007 May;16(5):659-78 [17461739.001]
  • [Cites] Leuk Res. 2007 Aug;31(8):1115-23 [17267032.001]
  • [Cites] Blood. 2007 Jul 1;110(1):313-22 [17363733.001]
  • [Cites] Stem Cells Dev. 2007 Jun;16(3):503-14 [17610380.001]
  • [Cites] Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R50-9 [17613547.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6417-24 [17616702.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4280-90 [17634558.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1827-8 [17460705.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5420-32 [17694083.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Sep;322(3):1084-92 [17569822.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]
  • [Cites] Cancer J. 2007 Nov-Dec;13(6):377-83 [18032975.001]
  • [Cites] Leukemia. 2008 Apr;22(4):740-7 [18079739.001]
  • [Cites] Br J Haematol. 2008 May;141(4):504-11 [18318760.001]
  • [Cites] Leukemia. 2008 May;22(5):965-70 [18385750.001]
  • [Cites] Leuk Res. 2008 Oct;32(10):1638-40 [18440067.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):375-80 [18636159.001]
  • [Cites] Blood. 2008 Aug 1;112(3):793-804 [18505786.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1636-8 [18305559.001]
  • [Cites] Stem Cells. 2008 Aug;26(8):1920-30 [18511598.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1886-93 [18591380.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6106-15 [18829489.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3065-72 [18650451.001]
  • [Cites] Haematologica. 2008 Nov;93(11):1635-44 [18815196.001]
  • [Cites] Leukemia. 2008 Nov;22(11):1990-8 [18843285.001]
  • [Cites] Int J Biochem Cell Biol. 2009 Jan;41(1):185-98 [18804549.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2231-2 [19052966.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2321-7 [19052980.001]
  • [Cites] Nat Rev Genet. 2009 Jan;10(1):32-42 [19065135.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6693-701 [15235588.001]
  • [Cites] Oncogene. 1998 Jul 2;16(26):3461-9 [9692554.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1239-44 [10022130.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):2705-12 [15517875.001]
  • [Cites] Int J Mol Med. 2005 Jan;15(1):169-72 [15583844.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1768-76 [15514006.001]
  • [Cites] Med Res Rev. 2005 May;25(3):261-309 [15717297.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] Cell Cycle. 2005 Jun;4(6):741-3 [15908787.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1579-89 [16015388.001]
  • [Cites] Gene. 2005 Dec 19;363:15-23 [16289629.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):38-51 [16397526.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1188-96 [16444746.001]
  • [Cites] Haematologica. 2006 Apr;91(4):513-21 [16533723.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3339-41 [16352805.001]
  • [Cites] Free Radic Biol Med. 2006 Jun 15;40(12):2175-82 [16785031.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):345-56 [17457302.001]
  • [Cites] Leukemia. 2009 Jan;23(1):180-2 [18509350.001]
  • [Cites] Cancer Lett. 2009 May 8;277(1):8-21 [18824292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 12;106(19):7751-5 [19416910.001]
  • [Cites] Ann Hematol. 2009 Jul;88(7):699-700 [19030859.001]
  • [Cites] Exp Cell Res. 2009 Jul 1;315(11):1809-18 [19268463.001]
  • [Cites] Eur J Haematol. 2009 Jul;83(1):48-56 [19226363.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8A):1437-50 [19522842.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7612-8 [19752087.001]
  • [Cites] Blood. 2009 Dec 3;114(24):5024-33 [19828702.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3109-17 [20130243.001]
  • [Cites] Leuk Res. 2010 Sep;34(9):1132-8 [20206383.001]
  • [Cites] Cancer Cell. 2010 May 18;17(5):427-42 [20478526.001]
  • [Cites] Blood. 2006 Jul 15;108(2):645-52 [16537804.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1058-64 [16861352.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1071-6 [16892059.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26729-34 [15937340.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5869-78 [17020995.001]
  • [Cites] Blood Cells Mol Dis. 2006 Nov-Dec;37(3):210-7 [16978890.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Ann Intern Med. 2006 Dec 19;145(12):913-23 [17179059.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):165-73 [16990584.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Leukemia. 2007 Mar;21(3):505-10 [17230231.001]
  • [Cites] Blood Cells Mol Dis. 2007 May-Jun;38(3):280-6 [17350297.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2049-55 [10766197.001]
  • [Cites] Mol Biol Cell. 2000 Jun;11(6):2069-83 [10848630.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20436-43 [10777477.001]
  • [Cites] Br J Haematol. 2000 Jul;110(1):2-11 [10930974.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39223-30 [11010972.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22491-9 [11304533.001]
  • [Cites] Cell Mol Life Sci. 2001 May;58(5-6):728-36 [11437234.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Mol Pharmacol. 2001 Oct;60(4):828-37 [11562446.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):683-93 [11870247.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Adv Cancer Res. 2002;86:41-65 [12374280.001]
  • [Cites] Semin Hematol. 2003 Jan;40(1):22-33 [12563609.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3236-9 [12446442.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5126-35 [12941844.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3765-74 [12893773.001]
  • (PMID = 21127942.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC3003795
  •  go-up   go-down


35. Buckley JM, Kuo CC, Cheng LC, Loo K, Motherway J, Slyfield C, Deviren V, Ames C: Relative strength of thoracic vertebrae in axial compression versus flexion. Spine J; 2009 Jun;9(6):478-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND CONTEXT: Noninvasive strength assessment techniques are the clinical standard in the diagnosis and treatment of osteoporotic vertebral fractures, and the efficacy of these protocols depends on their ability to predict vertebral strength at all at-risk spinal levels under multiple physiological loading conditions.
  • Quantitative computed tomography (QCT) scans were taken before mechanical testing and used to obtain bone mineral density (BMD) and "mechanics of solids" (MOS) measures, such as axial and bending rigidities.
  • For both compression and flexion loading modes, adjacent-level BMD and MOS metrics had approximately half the predictive capacity as same-level measurements, and BMD and MOS values were only moderately correlated across spinal levels.

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364678.001).
  • [ISSN] 1878-1632
  • [Journal-full-title] The spine journal : official journal of the North American Spine Society
  • [ISO-abbreviation] Spine J
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR49828
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Technical Report
  • [Publication-country] United States
  •  go-up   go-down


36. Baietto M, Wilson AD, Bassi D, Ferrini F: Evaluation of three electronic noses for detecting incipient wood decay. Sensors (Basel); 2010;10(2):1062-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The LibraNose quartz microbalance (QMB) e-nose generally provided higher levels of discrimination of sample unknowns, but not necessarily more accurate or effective detection than the AromaScan A32S conducting polymer and PEN3 metal-oxide (MOS) gas sensor e-noses for identifying and distinguishing woody samples containing different agents of wood decay.

  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sensors (Basel). 2009;9(7):5099-148 [22346690.001]
  • [Cites] Tree Physiol. 2000 Nov;20(17):1199-1203 [12651496.001]
  • [Cites] Arch Environ Health. 1999 Sep-Oct;54(5):347-52 [10501152.001]
  • [Cites] J Chem Ecol. 2006 Aug;32(8):1779-95 [16900432.001]
  • [Cites] J Stored Prod Res. 2000 Oct 15;36(4):319-340 [10880811.001]
  • [Cites] Mycol Res. 2004 Jul;108(Pt 7):806-14 [15446714.001]
  • [Cites] Phytopathology. 2004 May;94(5):419-31 [18943759.001]
  • (PMID = 22205858.001).
  • [ISSN] 1424-8220
  • [Journal-full-title] Sensors (Basel, Switzerland)
  • [ISO-abbreviation] Sensors (Basel)
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Volatile Organic Compounds
  • [Other-IDs] NLM/ PMC3244004
  • [Keywords] NOTNLM ; electronic aroma detection (major topic) / tree hazard assessment (major topic) / urban landscape tree species (major topic) / wood-rotting fungi (major topic)
  •  go-up   go-down


37. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G: Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS; 2010 Sep 24;24(15):2381-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The primary combined endpoint was days of hospitalization and outpatient therapeutic procedures, which were counted as one hospital day.
  • The primary combined endpoint was more frequent in the placebo than the prednisone arm {median hospital days 3 [interquartile range (IQR) 0-9] and 0 (IQR 0-3), respectively; P = 0.04}.
  • There were significantly greater improvements in symptoms, Karnofsky score, and quality of life (MOS-HIV) in the prednisone vs. the placebo arm at 2 and 4 weeks, but not at later time points.

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Steroids.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Non-ARV Adverse Events .
  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • Hazardous Substances Data Bank. PREDNISONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2004 Dec 1;39(11):1709-12 [15578375.001]
  • [Cites] Q J Med. 1992 Nov-Dec;85(307-308):855-60 [1484947.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):399-406 [15750393.001]
  • [Cites] MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112 [15841069.001]
  • [Cites] Antivir Ther. 2005;10(3):417-22 [15918332.001]
  • [Cites] Lancet Infect Dis. 2005 Jun;5(6):361-73 [15919622.001]
  • [Cites] AIDS. 2006 Jan 9;20(2):F1-7 [16511406.001]
  • [Cites] J Infect. 2006 Dec;53(6):357-63 [16487593.001]
  • [Cites] AIDS. 2007 Jan 30;21(3):335-41 [17255740.001]
  • [Cites] J Infect Dis. 2007 Aug 15;196 Suppl 1:S63-75 [17624828.001]
  • [Cites] Int J Tuberc Lung Dis. 2007 Dec;11(12):1282-9 [18229435.001]
  • [Cites] AIDS. 2008 Mar 12;22(5):663-5 [18317012.001]
  • [Cites] Lancet Infect Dis. 2008 Aug;8(8):516-23 [18652998.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Nov 15;178(10):1083-9 [18755923.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):667-76 [19191655.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):677-9 [19191656.001]
  • [Cites] J Infect Dis. 2009 Dec 1;200(11):1736-45 [19874177.001]
  • [Cites] Heart. 2000 Aug;84(2):183-8 [10908256.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62 [12588714.001]
  • [Cites] Int J Tuberc Lung Dis. 2003 Mar;7(3):208-13 [12661833.001]
  • [Cites] Thorax. 2004 Aug;59(8):704-7 [15282393.001]
  • [Cites] J Infect Dis. 2004 Sep 1;190(5):869-78 [15295690.001]
  • [Cites] Int J Tuberc Lung Dis. 2004 Sep;8(9):1114-9 [15455597.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1741-51 [15496623.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Mar 19;286(6369):923-5 [6403136.001]
  • [Cites] Lancet. 1988 Oct 1;2(8614):759-64 [2901610.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jul;158(1):157-61 [9655723.001]
  • [Cites] Qual Life Res. 1997 Aug;6(6):481-93 [9330549.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1574-6 [15577411.001]
  • (PMID = 20808204.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN21322548
  • [Grant] United States / FIC NIH HHS / TW / U2R TW007370; United States / PHS HHS / / 1U2RTW007373-01A1; United Kingdom / Wellcome Trust / / 081667; United Kingdom / Wellcome Trust / / 088316; United Kingdom / Medical Research Council / / MC/ U117588499; United States / FIC NIH HHS / TW / U2R TW007373; United States / FIC NIH HHS / TW / U2R TW007373-01A1; United Kingdom / Wellcome Trust / / 084323; United Kingdom / Wellcome Trust / / 072070; United States / PHS HHS / / U2RTW007370; United Kingdom / Wellcome Trust / / 084670; United States / FIC NIH HHS / TW / U2R TW007370-01A1
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Placebos; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ NIHMS229207; NLM/ PMC2940061
  •  go-up   go-down


38. Feng H, Hong L, Geng XS, Zhang H, Wang XS, Jiang XY: Second-look arthroscopic evaluation of bucket-handle meniscus tear repairs with anterior cruciate ligament reconstruction: 67 consecutive cases. Arthroscopy; 2008 Dec;24(12):1358-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In a series of 64 second-look cases with 67 repairs, which showed healing after an average of 26 months (range, 14 to 66 mos), 55 repairs (82.1%) were completely healed (and clinically asymptomatic) in 53 cases; 5 cases (5 repairs; 7.5%) had joint line tenderness (incompletely healed and clinically asymptomatic); and 7 repairs (6 medial, and 1 lateral; 10.4%) failed, with recurrent locking or catching in 4 cases (and clinically asymptomatic in 2 cases).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038706.001).
  • [ISSN] 1526-3231
  • [Journal-full-title] Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association
  • [ISO-abbreviation] Arthroscopy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Holmes WC, Ruocco JE: Test-retest evaluation of HAT-QoL and SF-36 in an HIV-seropositive sample. AIDS Care; 2008 Oct;20(9):1084-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to correct previously reported psychometric and content problems of the HIV/AIDS-Targeted Quality of Life Instrument (HAT-QoL) and to assess test-retest reliability of this revised HAT-QoL as well as the MOS 36-Item Short-Form Health Survey (SF-36) when used in an HIV-seropositive outpatient sample.
  • [MeSH-minor] Adult. Disease Progression. Factor Analysis, Statistical. Female. Focus Groups. Humans. Male. Psychometrics. Sickness Impact Profile

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608069.001).
  • [ISSN] 1360-0451
  • [Journal-full-title] AIDS care
  • [ISO-abbreviation] AIDS Care
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI01482
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


40. Kakinuma H, Ozaki M, Sato H, Takahashi H: Variation in GABA-A subunit gene copy number in an autistic patient with mosaic 4 p duplication (p12p16). Am J Med Genet B Neuropsychiatr Genet; 2008 Sep 5;147B(6):973-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autism has been associated with chromosomal aberrations, including duplications at chromosome 4, and the identification of genetic factors contributing to the etiology of this disease is the focus of much research.
  • Here we report a Japanese girl with mosaic of chromosome 4p duplication, mos 46,XX,dup(4)(p12p16)[54]/46,XX[6], who was diagnosed with autism at 3 years of age.
  • [MeSH-major] Autistic Disorder / genetics. Chromosomes, Human, Pair 4. Gene Dosage. Gene Duplication. Mosaicism. Receptors, GABA-A / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc.
  • (PMID = 18163449.001).
  • [ISSN] 1552-485X
  • [Journal-full-title] American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
  • [ISO-abbreviation] Am. J. Med. Genet. B Neuropsychiatr. Genet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Subunits; 0 / Receptors, GABA-A
  •  go-up   go-down


41. Xu ZQ, Sun XM: [New insight into pathogenesis of idiopathic myelofibrosis--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec;15(6):1330-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New insight into pathogenesis of idiopathic myelofibrosis--review].
  • Idiopathic myelofibrosis is a type of chronic myeloproliferative disorders characterized by splenomegaly, a leukoerythroblastic blood picture, teardrop poikilocytosis, in various degrees of bone marrow fibrosis and extramedullary hematopoiesis.
  • In this paper, the biological characters and pathogenesis of idiopathic myelofibrosis such as mutation of tyrosine kinase receptor, mutation of GABA transporter 1, JAK2 mutation and c-MPl mutation, as well as other pathogenesis related with idiopathic myelofibrosis were reviewed.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088495.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / GABA Plasma Membrane Transport Proteins; 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 31
  •  go-up   go-down


42. Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W: The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost; 2006 Jun;32(4 Pt 2):307-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
  • The clinical criteria according to the Polycythemia Vera Study Group (PVSG) do not distinguish between essential thrombocythemia (ET), thrombocythemia associated with early-stage polycythemia vera (PV) and prefibrotic chronic idiopathic myelofibrosis (CIMF).
  • The classification of myeloproliferative disorders (MPDs), proposed by the World Health Organization (WHO) in 2001, is a compromise of the clinical PVSG and WHO bone marrow criteria, and excludes early stages of ET and PV.
  • The updated European clinical and pathological criteria combine the WHO bone marrow criteria with established and new clinical, laboratory, biological, and molecular MPD markers.
  • This allows clinicians and pathologists to diagnose early-stage MPD and to differentiate ET, PV, and prefibrotic chronic idiopathic myelofibrosis (CIMF).
  • Depending on laboratory tests and diagnostic criteria used, the population of the MPD patients defined as ET, PV, and CIMF are heterogeneous at the clinical, laboratory, and biological and pathological levels.
  • The recent discovery of the JAK2 V617F mutation, which is the cause of a distinct trilinear MPD in its manifold clinical manifestations during long-term follow-up, increases the specificity of a positive JAK2 V617F polymerase chain reaction (PCR) test for the diagnosis of MPD (near 100%), but only half of the ET and CIMF patients according to the PVSG (sensitivity 50%) and the majority of PV patients (sensitivity 95%) are JAK2 V617F positive.
  • A comparison of the laboratory features of JAK2 V617-positive and JAK2 wild-type ET patients clearly showed that JAK2 V617-positive ET is characterized by higher values for hemoglobin, hematocrit, and neutrophil counts; lower values for serum erythropoietin (EPO) levels, serum ferritin, and mean corpuscular volume; and by increased cellularity of the bone marrow in biopsy material.
  • In contrast, the JAK2 wild-type ET patients had significantly higher platelet counts and usually had a clinical picture of ET with normal serum EPO levels, PRV-1 expression, and leukocyte alkaline phosphatase score, and a typical WHO ET bone marrow picture.
  • The clinical and pathological data on JAK2 V617F-positive MPD patients suggest that the JAK2 V617F mutation defines one disease entity with several sequential steps of ET, PV, and secondary myelofibrosis during long-term follow-up, and that the wild-type JAK2 MPDs may represent another distinct entity with a related but different molecular etiology.
  • MPD-specific markers such as serum EPO, endogenous erythroid colony formation (EEC), and JAK2 V617F have high specificities, but the sensitivities are not high enough to detect the early stages of the MPDs, ET, PV, and prefibrotic CIMF.
  • Bone marrow histopathology in addition to clinical, laboratory, biological, and molecular markers, including the JAK2 V617 PCR test, serum EPO, PRV-1, EEC, LAP score, peripheral blood parameters, and spleen size on echogram will detect the early stages of MPD and allows diagnostic differentiation of the three primary MPDs (ET, PV, and CIMF) in both JAK2 V617F-positive and JAK2 wild-type MPD patients.
  • [MeSH-major] Myeloproliferative Disorders / diagnosis. Philadelphia Chromosome. World Health Organization
  • [MeSH-minor] Biomarkers / blood. Bone Marrow / pathology. Chronic Disease. Diagnosis, Differential. Europe. History, 21st Century. Humans. Janus Kinase 2. Point Mutation. Practice Guidelines as Topic. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810609.001).
  • [ISSN] 0094-6176
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Multicenter Study; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 232
  •  go-up   go-down


43. Tang JW, Ngai KL, Lam WY, Chan PK: Seasonality of influenza A(H3N2) virus: a Hong Kong perspective (1997-2006). PLoS One; 2008;3(7):e2768
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These dated sequences were analyzed with influenza A(H3N2) vaccine strain sequences (Syd/5/97, Mos/10/99, Fuj/411/02, Cal/7/04) and 315 other publicly available dated sequences from elsewhere, worldwide.
  • Before 2001, the Hong Kong HA and NA sequences clustered more closely with the older vaccine sequences (Syd/5/97, Mos/10/99) than did sequences from elsewhere.
  • However, at least one example from Hong Kong was found suggesting that in some years, influenza A(H3N2) viruses may persist in the same location, perhaps continuing to circulate, sub-clinically, at low levels between seasons, to re-emerge in the influenza season the following year, relatively unchanged.
  • However, occasionally, some viruses may remain within a single location and continue to circulate within that population, to re-emerge during the next influenza season, with relatively little genetic change.

  • MedlinePlus Health Information. consumer health - Flu.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Paediatr Respir Rev. 2003 Jun;4(2):105-11 [12758047.001]
  • [Cites] Nature. 2003 Mar 27;422(6930):428-33 [12660783.001]
  • [Cites] Theor Popul Biol. 2004 Mar;65(2):179-91 [14766191.001]
  • [Cites] Brief Bioinform. 2004 Mar;5(1):82-7 [15153308.001]
  • [Cites] Science. 2004 Jul 16;305(5682):371-6 [15218094.001]
  • [Cites] Lancet. 1982 Oct 9;2(8302):812-3 [6126676.001]
  • [Cites] Rev Infect Dis. 1989 May-Jun;11(3):494-7 [2665004.001]
  • [Cites] Bioinformatics. 1998;14(9):817-8 [9918953.001]
  • [Cites] Lancet Infect Dis. 2004 Nov;4(11):704-8 [15522683.001]
  • [Cites] Eur J Epidemiol. 2004;19(11):1055-9 [15648600.001]
  • [Cites] Vaccine. 2005 Mar 14;23(16):1981-5 [15734071.001]
  • [Cites] PLoS Biol. 2005 Sep;3(9):e300 [16026181.001]
  • [Cites] Nature. 2005 Oct 20;437(7062):1162-6 [16208317.001]
  • [Cites] N Engl J Med. 2005 Dec 15;353(24):2559-67 [16354892.001]
  • [Cites] Math Biosci. 2006 Apr;200(2):152-69 [16504214.001]
  • [Cites] PLoS Med. 2006 Apr;3(4):e89 [16509764.001]
  • [Cites] PLoS Med. 2006 Apr;3(4):e121 [16515368.001]
  • [Cites] Science. 2006 Apr 21;312(5772):392-4 [16627736.001]
  • [Cites] Proc Biol Sci. 2006 Jun 7;273(1592):1307-16 [16777717.001]
  • [Cites] Science. 2006 Dec 22;314(5807):1884-6 [17185589.001]
  • [Cites] J Virol. 2007 Jun;81(11):5429-36 [17182688.001]
  • [Cites] PLoS One. 2007;2(5):e489 [17534439.001]
  • [Cites] Lancet Infect Dis. 2007 Aug;7(8):543-8 [17646027.001]
  • [Cites] PLoS Pathog. 2006 Dec;2(12):e125 [17140286.001]
  • [Cites] PLoS Pathog. 2007 Sep 14;3(9):1220-8 [17941707.001]
  • [Cites] PLoS Pathog. 2007 Oct 19;3(10):1470-6 [17953482.001]
  • [Cites] PLoS One. 2007;2(12):e1296 [18074020.001]
  • [Cites] Science. 2008 Apr 18;320(5874):340-6 [18420927.001]
  • [Cites] Nature. 2008 May 29;453(7195):615-9 [18418375.001]
  • [Cites] Science. 2006 Dec 22;314(5807):1898-903 [17185596.001]
  • [Cites] Nat Rev Genet. 2007 Mar;8(3):196-205 [17262054.001]
  • [Cites] Nature. 2007 Mar 29;446(7135):533-6 [17392785.001]
  • [Cites] Annu Rev Med. 2000;51:407-21 [10774473.001]
  • [Cites] J Math Biol. 2003 Jun;46(6):504-36 [12783180.001]
  • (PMID = 18648550.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.18 / Neuraminidase
  • [Other-IDs] NLM/ PMC2481298
  •  go-up   go-down


44. Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC: The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol; 2007 Sep;20(9):929-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
  • Extramedullary hematopoiesis (EMH) in the spleen is a characteristic feature of the chronic myeloproliferative disorders (CMPDs) and various other neoplastic or reactive myeloid conditions.
  • The V617F mutation in the Janus Kinase 2 gene (JAK2(V617F)) was recently shown to be frequently and preferentially present in the peripheral blood and bone marrow cells of CMPD patients, and the resulting dysregulation of its downstream targets is important to CMPD pathogenesis.
  • JAK2(V617F) was detected by real-time PCR melting curve analysis in 22 specimens, including 11/17 chronic idiopathic myelofibrosis, 7/7 polycythemia vera, 1/1 essential thrombocythemia, 1/3 CMPD unclassifiable, 1/5 chronic myelomonocytic leukemia, 0/5 chronic myelogenous leukemia, 1/3 myelodysplastic syndrome and 0/6 acute myeloblastic leukemia cases, whereas only the JAK2 wild-type allele was detected in the other 25.
  • Nineteen of 20 cases with adequate bone marrow samples available for molecular examination demonstrated concordant JAK2 genotypes.
  • Laser-capture microdissection was then used to enrich the EMH and non-EMH splenic cell fractions, confirming that the mutant alleles specifically originated from the EMH cells.
  • Thus, JAK2(V617F) is frequently present in splenic EMH cells associated with CMPD, but it is rarely identified in splenic EMH cells associated with other myeloid disorders.
  • Our results indicate that the precursor cells leading to extramedullary hematopoietic expansion in CMPD most likely originate from the transformed bone marrow clone.
  • Also, dysregulation of downstream pathways such as Bcl-xL may be important to CMPD disease pathogenesis in the spleen.
  • [MeSH-major] Hematopoiesis, Extramedullary / genetics. Janus Kinase 2 / genetics. Mutation. Myeloproliferative Disorders / genetics
  • [MeSH-minor] Bone Marrow Cells / chemistry. Bone Marrow Cells / enzymology. Chronic Disease. Humans. Immunohistochemistry. Lasers. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / enzymology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myelomonocytic, Chronic / blood. Leukemia, Myelomonocytic, Chronic / enzymology. Leukemia, Myelomonocytic, Chronic / genetics. Megakaryocytes / chemistry. Megakaryocytes / enzymology. Microdissection / methods. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / enzymology. Myelodysplastic Syndromes / genetics. Polycythemia Vera / blood. Polycythemia Vera / enzymology. Polycythemia Vera / genetics. Polymerase Chain Reaction. Primary Myelofibrosis / blood. Primary Myelofibrosis / enzymology. Primary Myelofibrosis / genetics. Retrospective Studies. Spleen / chemistry. Spleen / enzymology. Thrombocythemia, Essential / blood. Thrombocythemia, Essential / enzymology. Thrombocythemia, Essential / genetics. United States. bcl-X Protein / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643100.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / bcl-X Protein; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


45. Bellipanni G, Varga M, Maegawa S, Imai Y, Kelly C, Myers AP, Chu F, Talbot WS, Weinberg ES: Essential and opposing roles of zebrafish beta-catenins in the formation of dorsal axial structures and neurectoderm. Development; 2006 Apr;133(7):1299-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reduction of beta-catenin-2 function in wild-type embryos by injection of morpholino antisense oligonucleotides (MOs) specific for this gene (MO2) results in the same ventralized phenotypes as seen in ichabod embryos, and administration of MO2 to ichabod embryos increases the extent of ventralization.
  • MOs directed against beta-catenin-1 (MO1), by contrast, had no ventralizing effect on wild-type embryos. beta-catenin-2 is thus specifically required for organizer formation and this function is apparently required maternally, because the ichabod mutation causes a reduction in maternal transcription of the gene and a reduced level of beta-catenin-2 protein in the early embryo.
  • Using a combination of MO1 and MO2 in wild-type embryos, or by injecting solely MO1 in ichabod embryos, we obtain expression of a wide spectrum of neural markers in apparently appropriate anteroposterior pattern.


46. Carod-Artal FJ, Ferreira Coral L, Trizotto DS, Menezes Moreira C: Poststroke depression: prevalence and determinants in Brazilian stroke patients. Cerebrovasc Dis; 2009;28(2):157-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients were evaluated by means of the NIH Stroke Scale, Mini-Mental State Examination, Barthel Index, Lawton Scale, modified Rankin Scale, Hospital Anxiety and Depression Scale (HADS), Geriatric Depression Scale (GDS) and MOS-Short Form 36.
  • Patients with a HADS-depression subscale score > or = 11 and/or GDS score > or = 8 were classified as depressed.
  • CONCLUSIONS: PSD was highly prevalent in the chronic phase of stroke.
  • [MeSH-minor] Activities of Daily Living. Adult. Aged. Anxiety / ethnology. Anxiety / etiology. Brazil / epidemiology. Chronic Disease. Cross-Sectional Studies. Diabetes Mellitus / psychology. Disability Evaluation. Educational Status. Employment. Female. Humans. Male. Middle Aged. Prevalence. Psychiatric Status Rating Scales. Regression Analysis. Risk Assessment. Risk Factors. Severity of Illness Index

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19556768.001).
  • [ISSN] 1421-9786
  • [Journal-full-title] Cerebrovascular diseases (Basel, Switzerland)
  • [ISO-abbreviation] Cerebrovasc. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


47. Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L, Orn T, Holberg MA, Kirksaether N, Grill V: Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab; 2008 May;10(5):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • QL after 4 years as measured by the MOS 36-item Short-Form Health Survey (SF-36) form was not significantly altered.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394534.001).
  • [ISSN] 1463-1326
  • [Journal-full-title] Diabetes, obesity & metabolism
  • [ISO-abbreviation] Diabetes Obes Metab
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin, Long-Acting; 0 / Lipids; 9007-92-5 / Glucagon; 9035-68-1 / Proinsulin; SX6K58TVWC / Glyburide
  •  go-up   go-down


48. Beaupre GS, Lew HL: Bone-density changes after stroke. Am J Phys Med Rehabil; 2006 May;85(5):464-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone-density changes after stroke.
  • It has been many years since bone loss and fracture risk were first recognized as serious complications of stroke.
  • Hip fracture is associated with a substantial increase in morbidity and mortality for stroke survivors, and therefore, assessing and maintaining skeletal health after stroke should be an important clinical goal.
  • Recent long-term, prospective studies have illustrated a highly nonuniform pattern of bone changes after stroke.
  • In general, there is significant bone loss on the paretic side, which is greatest in those patients with the most severe functional deficits.
  • In some patients, bone loss in the paretic arm during the first year after stroke is the equivalent of >20 yrs of bone loss in healthy individuals of comparable age.
  • Bone density in the nonparetic upper limb can actually increase after stroke, consistent with an increase in habitual use of the nonparetic hand.
  • Bone density in the paretic lower limb can decrease by >10% in <1 yr, with smaller decreases being typical for the nonparetic lower limb.
  • Despite the recent increase in the number of prospective, longitudinal studies, important questions about bone changes after stroke remain unanswered.
  • Longer-term studies quantifying bone loss for periods of >12 mos poststroke are needed to determine how long excess bone loss continues after stroke.
  • Studies with more subjects and with more varied disability levels are needed to better understand the relationships between functional deficits and bone loss.
  • New metrics are needed to quantify the intensity and duration of physical activity in the upper and lower limbs that are consistent with previous research on the role of mechanical stimuli in bone adaptation.
  • Finally, an assessment of skeletal health and the factors that affect bone quantity and quality should be a standard component in the clinical management of all survivors of stroke.

  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Stroke.
  • MedlinePlus Health Information. consumer health - Stroke Rehabilitation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628156.001).
  • [ISSN] 0894-9115
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 56
  •  go-up   go-down


49. Gelatti U, Samani F, Donato F, Covolo L, Mazzaglia G, Cremaschini F, Simon G, Leggieri G, Balestrieri M: Health-related quality of life in older people using benzodiazepines: a cross-sectional study. Ann Ig; 2006 Jul-Aug;18(4):313-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All subjects aged 65-84 years attending their General Practitioners were invited to fill in a questionnaire about their consumption of BDZ and all the subjects consuming BDZ to fill in the Medical Outcome Measures Short Form-36 (MOS SF-36) and the Primary Care Evaluation of Mental Disorders (PRIME-MD) questionnaires.
  • A total of 2,246 subjects used BDZ and 1,109 (49.4%) of them filled in the MOS SF-36 questionnaire.
  • The presence of sleep disorders and the characteristics of the BDZ used were not associated with any score in the MOS SF-36 questionnaire, whereas the Prime diagnosis was the most important predictor, since subjects with depression and/or anxiety had a lower mean score on each scale than subjects without disorders.

  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063630.001).
  • [ISSN] 1120-9135
  • [Journal-full-title] Annali di igiene : medicina preventiva e di comunità
  • [ISO-abbreviation] Ann Ig
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 12794-10-4 / Benzodiazepines
  •  go-up   go-down


50. Berrebi A, Feldberg E, Spivak I, Shvidel L: Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly. Haematologica; 2007 Feb;92(2):e15-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
  • We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Primary Myelofibrosis / drug therapy. Thalidomide / administration & dosage
  • [MeSH-minor] Aged, 80 and over. Blood Transfusion. Bone Marrow / pathology. Combined Modality Therapy. Drug Therapy, Combination. Fluoxymesterone / administration & dosage. Fluoxymesterone / therapeutic use. Folic Acid / administration & dosage. Folic Acid / therapeutic use. Humans. Male. Prednisone / administration & dosage. Prednisone / therapeutic use. Remission Induction. Splenomegaly / etiology. Vitamin B Complex / administration & dosage. Vitamin B Complex / therapeutic use

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Splenomegaly.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. FLUOXYMESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405746.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 12001-76-2 / Vitamin B Complex; 4Z8R6ORS6L / Thalidomide; 935E97BOY8 / Folic Acid; 9JU12S4YFY / Fluoxymesterone; VB0R961HZT / Prednisone
  •  go-up   go-down


51. Khanna V, Nama S, Tailor R, Muthukrishnan A: Myelofibrosis on 18F-FDG-PET/CT in a case suspicious for post-transplant lymphoproliferative disorder. Hell J Nucl Med; 2009 Sep-Dec;12(3):274-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelofibrosis on 18F-FDG-PET/CT in a case suspicious for post-transplant lymphoproliferative disorder.
  • We report a case of a 61-year-old man with clinical suspicion of post-transplant lymphoproliferative disorder (PTLD) where (18)F-FDG-PET/CT (computerized tomography) was helpful in identifying myelofibrosis.
  • This paper aims to reveal the potential diagnostic value of PET/CT as an imaging modality in the evaluation of myelofibrosis.
  • [MeSH-major] Fluorodeoxyglucose F18. Heart Transplantation / adverse effects. Positron-Emission Tomography / methods. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / etiology. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Diagnosis, Differential. Humans. Leukemia, Large Granular Lymphocytic / etiology. Leukemia, Large Granular Lymphocytic / radionuclide imaging. Male. Middle Aged. Radiopharmaceuticals. Subtraction Technique

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936343.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Wen XD, Li YW, Wang J, Jiao H: NO adsorption on MoS(x) clusters: a density functional theory study. J Phys Chem B; 2006 Oct 26;110(42):21060-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NO adsorption on MoS(x) clusters: a density functional theory study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048926.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Zhang YQ, Wang YX, Xu GZ, Song HY, Wang WJ: [Influence of CRX gene on development of photoreceptors in zebrafish]. Zhonghua Yan Ke Za Zhi; 2008 May;44(5):448-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CRX-MOs was microinjected into the zygote of zebrafish.
  • RESULTS: There were no obvious histological changes in optical microscope observation after CRX-MOs microinjection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953902.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Trans-Activators; 0 / cone rod homeobox protein
  •  go-up   go-down


54. Ru YX, Zhao SX, Liu EB, Yang QY, Liu JH, Pang TX, Chen HS: Ultrastructural characteristics of bone marrow in patients with hematological disease: a study of 13 cases. Ultrastruct Pathol; 2007 Sep-Oct;31(5):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrastructural characteristics of bone marrow in patients with hematological disease: a study of 13 cases.
  • There are few transmission electron microscopic studies on bone marrow biopsies of patients with hematological disease owing to the difficulty of overcoming the artifacts of decalcification.
  • Following the fixation of bone marrow biopsies thoroughly before a mild decalcification procedure, ultrastructural studies were performed on 13 patients with varied hematological diseases.
  • In addition, excessive blood cell death in leukemia, apoptosis, and macrophage phagocytosis in myelodysplastic syndrome and polycythemia vera, as well as degranulation of eosinophils and megakaryocytes in chronic idiopathic myelofibrosis were predominant, respectively.
  • The observations suggest that polyclonal fibroblast proliferation and extracellular matrix accumulation may result from inflammation resulting from excessive cell death and active material release of blood cells in the bone marrow of patients with hematological disease.
  • [MeSH-major] Bone Marrow / ultrastructure. Bone Marrow Cells / ultrastructure. Hematologic Diseases / pathology. Microscopy, Electron, Transmission / methods
  • [MeSH-minor] Adolescent. Adult. Biopsy. Child. Chronic Disease. Cytoplasmic Structures / ultrastructure. Extracellular Matrix / ultrastructure. Female. Fibroblasts / ultrastructure. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Leukemia, Plasma Cell / genetics. Leukemia, Plasma Cell / pathology. Male. Middle Aged. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / pathology. Polycythemia Vera / genetics. Polycythemia Vera / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963181.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Babikako HM, Neuhauser D, Katamba A, Mupere E: Feasibility, reliability and validity of health-related quality of life questionnaire among adult pulmonary tuberculosis patients in urban Uganda: cross-sectional study. Health Qual Life Outcomes; 2010;8:93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We established the feasibility, reliability, and validity of the Medical Outcomes Survey (MOS) in assessing HRQoL among patients with pulmonary tuberculosis in Kampala, Uganda.
  • METHODS: In a cross-sectional study, 133 patients with known HIV status and confirmed pulmonary TB disease were recruited from one public and one private hospital.
  • A translated and culturally adapted standardized 35-item MOS instrument was administered by trained interviewers.
  • The visual analogue scale (VAS) was used to cross-validate the MOS.
  • RESULTS: The MOS instrument was highly acceptable and easily administered.
  • All subscales of the MOS demonstrated acceptable internal consistency with Cronbach's alpha above 0.70 except for role function that had 0.65.
  • Each dimension of the MOS was highly correlated with the dimension measured concurrently using the VAS providing evidence of validity.
  • Completion of 8 months TB therapy among patients who were recruited from the public hospital was associated with a significant increase in HRQoL scores for quality of life subscale (1.26 (95% CI; 1.08-1.49)), physical health summary score (1.22 995% CI; 1.04-1.43)), and VAS (1.08 (95% CI; 1.01-1.15)) relative to patients who were recruited from the private hospital.
  • CONCLUSION: The study provides evidence that the MOS instrument is valid, and reliably measures HRQoL among TB patients, and can be used in a wide variety of study populations.

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Epidemiol. 2001 Nov;54(11):1081-5 [11675158.001]
  • [Cites] AIDS Care. 2004 Jan;16(1):81-94 [14660146.001]
  • [Cites] J Health Econ. 1986 Mar;5(1):1-30 [10311607.001]
  • [Cites] J Clin Epidemiol. 1989;42(5):459-71 [2732774.001]
  • [Cites] Health Policy. 1990 Dec;16(3):199-208 [10109801.001]
  • [Cites] Bull World Health Organ. 1992;70(1):17-21 [1568278.001]
  • [Cites] Appl Nurs Res. 2007 Nov;20(4):164-70 [17996802.001]
  • [Cites] Soc Sci Med. 1995 Dec;41(12):1685-92 [8746868.001]
  • [Cites] Qual Life Res. 1997 Aug;6(6):481-93 [9330549.001]
  • [Cites] Qual Life Res. 1997 Aug;6(6):531-54 [9330553.001]
  • [Cites] Med Care. 1998 Feb;36(2):126-37 [9475468.001]
  • [Cites] Int J Tuberc Lung Dis. 1999 Oct;3(10):869-77 [10524583.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • (PMID = 20813062.001).
  • [ISSN] 1477-7525
  • [Journal-full-title] Health and quality of life outcomes
  • [ISO-abbreviation] Health Qual Life Outcomes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2944342
  •  go-up   go-down


56. Martin S, Chandran A, Zografos L, Zlateva G: Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales. Health Qual Life Outcomes; 2009;7:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both the Sleep Quality Numeric Rating Scale (NRS) and the Medical Outcomes Study Sleep Scale (MOS-Sleep) have demonstrated positive psychometric properties in patients with FM.
  • METHODS: Qualitative interviews were conducted in Raleigh, North Carolina and Detroit, Michigan with 20 adults who reported a physician diagnosis of FM.
  • Participants found the 12-item MOS-Sleep to be appropriate and relevant; 19 participants indicated the measure captured all of their sleep-related symptoms.
  • However, areas for potential modification were identified, such as the need to separate the item regarding awakening short of breath and awakening with a headache into two separate questions.
  • Modifications to the MOS-Sleep may improve the psychometric properties and relevance to patients with FM.

  • Genetic Alliance. consumer health - Fibromyalgia.
  • MedlinePlus Health Information. consumer health - Fibromyalgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sleep Med. 2009 Aug;10(7):766-70 [19185539.001]
  • [Cites] Patient Educ Couns. 2008 Oct;73(1):114-20 [18640807.001]
  • [Cites] Arthritis Care Res. 2000 Feb;13(1):42-50 [11094925.001]
  • [Cites] Qual Health Res. 2002 Feb;12(2):148-60 [11837367.001]
  • [Cites] Scand J Caring Sci. 2000;14(1):29-36 [12035259.001]
  • [Cites] Res Theory Nurs Pract. 2002 Spring;16(1):19-31 [12371466.001]
  • [Cites] Psychiatry Res. 1989 May;28(2):193-213 [2748771.001]
  • [Cites] Arthritis Rheum. 1990 Feb;33(2):160-72 [2306288.001]
  • [Cites] Arthritis Rheum. 1995 Jan;38(1):19-28 [7818567.001]
  • [Cites] Scand J Caring Sci. 1995;9(2):77-86 [7617995.001]
  • [Cites] Pain. 1996 Feb;64(2):211-9 [8740597.001]
  • [Cites] Scand J Caring Sci. 1998;12(2):95-103 [9801630.001]
  • [Cites] Scand J Prim Health Care. 1999 Mar;17(1):11-6 [10229986.001]
  • [Cites] Sleep Med. 2005 Jan;6(1):41-4 [15680294.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1264-73 [15818684.001]
  • [Cites] J Rheumatol. 2006 Oct;33(10):1942-51 [16960928.001]
  • [Cites] Clin Nurs Res. 2006 Nov;15(4):258-73 [17056769.001]
  • [Cites] J Psychosom Res. 2007 Feb;62(2):145-51 [17270572.001]
  • [Cites] Eur J Pain. 2007 Apr;11(3):329-40 [16765622.001]
  • [Cites] Clin Ther. 2006 Dec;28(12):2119-32 [17296468.001]
  • [Cites] BMC Musculoskelet Disord. 2007;8:27 [17349056.001]
  • [Cites] Value Health. 2007 Nov-Dec;10 Suppl 2:S86-93 [17995478.001]
  • [Cites] Value Health. 2007 Nov-Dec;10 Suppl 2:S94-S105 [17995479.001]
  • [Cites] J Rheumatol. 2008 Mar;35(3):502-14 [18278830.001]
  • [Cites] Pain. 2008 Jun;136(3):419-31 [18400400.001]
  • [Cites] Arthritis Rheum. 2008 Jul 15;59(7):952-60 [18576290.001]
  • [Cites] Arthritis Rheum. 2008 Jul 15;59(7):961-7 [18576297.001]
  • [Cites] J Pain. 2008 Sep;9(9):792-805 [18524684.001]
  • [Cites] Can Fam Physician. 2000 May;46:1100-6 [10845136.001]
  • (PMID = 19591683.001).
  • [ISSN] 1477-7525
  • [Journal-full-title] Health and quality of life outcomes
  • [ISO-abbreviation] Health Qual Life Outcomes
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2717926
  •  go-up   go-down


57. Malcolm JB, Logan JE, Given RW, Lance R, Vingan H, Shaves SC, Fabrizio M: Renal functional outcomes after cryoablation of small renal masses. J Endourol; 2010 Mar;24(3):479-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic kidney disease (CKD) was defined as a serum creatinine level >2.0 mg/dL or eGFR <60 mL/min/1.73 m(2).
  • Mean follow-up was 30 months (range 13-63 mos).
  • Comorbid conditions were prevalent: 77% hypertension, 35% hyperlipidemia, 31% diabetes mellitus, 39% tobacco use, and 32% heart disease (coronary artery disease/congestive heart failure).
  • De novo CKD was noted in 5 of 45 (11%) patients.
  • Patients in whom de novo CKD developed had lower pretreatment eGFR (71.0 vs 98.4 60 mL/min/1.73 m(2), P = 0.03) and larger tumor size (2.94 vs 2.19 cm, P = 0.04) compared with patients who were maintaining normal renal function.
  • When CKD was defined as creatinine level >2.0 mg/dL, only one and six patients were identified with preoperative and de novo CKD, respectively.
  • CONCLUSIONS: In a cohort of renal cryosurgery patients who were characterized by highly prevalent medical comorbidities, renal function was generally well maintained, with a low rate of de novo CKD based on eGFR calculations.


58. Duncan JA, Calkins DE, Chavarha M: Secondary orbital effect in the electrocyclic ring closure of 7-Azahepta-1,2,4,6-tetraeneA CASSCF molecular orbital study. J Am Chem Soc; 2008 May 28;130(21):6740-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 3 --> 4 rearrangement has been studied computationally with density functional theory (DFT) by others, leading to disagreement over whether it is pseudopericyclic (de Lera, A. R.
  • 2001, 40, 557-561; de Lera, A. R.
  • Furthermore, comparison of orbital correlation diagrams constructed entirely from localized complete active space (CAS) molecular orbitals (MOs) for the electrocyclizations of 3, 5, 7, 9, and 10 suggest that it is the highest occupied delocalized pi-MO of 3 that is primarily responsible for sigma-bond formation in 4, not the terminal allenyl pi-bond MO.


59. Isbir SC, Ak K, Tekeli A, Civelek A, Atalan N, Arsan S: Coronary artery bypass grafting in idiopathic myelofibrosis: a case report. Heart Surg Forum; 2007;10(1):E55-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coronary artery bypass grafting in idiopathic myelofibrosis: a case report.
  • The concomitant presence of myeloproliferative disorders and the need for coronary artery bypass surgery is a surgical dilemma.
  • We report a patient who had idiopathic myelofibrosis and underwent a successful coronary artery bypass surgery.
  • [MeSH-major] Coronary Artery Bypass. Coronary Stenosis / surgery. Primary Myelofibrosis / complications

  • Genetic Alliance. consumer health - Myelofibrosis.
  • MedlinePlus Health Information. consumer health - Coronary Artery Bypass Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162404.001).
  • [ISSN] 1522-6662
  • [Journal-full-title] The heart surgery forum
  • [ISO-abbreviation] Heart Surg Forum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Sheng T, Dechert S, Hyla-Kryspin I, Winter RF, Meyer F: Redox site confinement in highly unsymmetric dimanganese complexes. Inorg Chem; 2005 May 30;44(11):3863-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They can be described as hybrid organometallic/Werner-type systems that consist of a low-spin CpMn(I)(CO)2 subunit (Mn1) and a proximate tripodal tetradentate {N4} binding pocket accommodating a high-spin Mn(II) ion (Mn2), with Mn...Mn distances of approximately 4.3 A and different coligands bound to Mn2.
  • Density functional theory (DFT) calculations (both the hybrid B3LYP and the pure BP86 functionals and the all-electron basis sets 6-311G and 6-311G*) confirm that the valence alpha and beta Kohn-Sham molecular orbitals (MOs) of these mixed-valent Mn(I)Mn(II) compounds have predominant Mn(3d) character and an almost perfectly localized nature: all five unpaired electrons are essentially localized at the Werner-type Mn2, whereas Mn1 possesses an effective closed-shell structure with the MOs of highest energy centered there.
  • UV/vis and IR spectroelectrochemistry as well as a detailed theoretical analysis reveal that the redox process takes place with strict site control at the organometallic subunit, while it does not significantly influence the spin and charge distribution on the Werner-type site.
  • These systems thus represent an exceptional example of the effect the unsymmetry of a dinucleating ligand scaffold has on the spin and charge distribution in homobimetallic complexes and might offer interesting prospects for the study of the cooperative effects of bimetallic arrays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907112.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Zhu S, Lo GQ, Kwong DL: Theoretical investigation of silicon MOS-type plasmonic slot waveguide based MZI modulators. Opt Express; 2010 Dec 20;18(26):27802-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Theoretical investigation of silicon MOS-type plasmonic slot waveguide based MZI modulators.
  • It is composed of horizontal metal-SiO2-Si-metal plasmonic slot waveguides for phase shifting and ultracompact V-shape splitter/combiner to link the plasmonic slot waveguides and the conventional Si dielectric waveguides.
  • The proposed modulator can be directly integrated into existing Si electronic photonic integrated circuits (EPICs) and be fabricated using standard Si complementary metal-oxide-semiconductor (CMOS) technology.
  • For a modulator with 3-µm-long Ag-SiO2(2 nm)-Si(50 nm)-Ag phase shifter and 0.35-µm-long splitter/combiner operating at 1.55-µm wavelength, simulation shows an insertion loss of ~-8 dB, an extinction ratio of ~7.3 dB - with a switching voltage of ~5.6 V, and a bandwidth of ~500 GHz.

  • Hazardous Substances Data Bank. Silicon, Elemental .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197054.001).
  • [ISSN] 1094-4087
  • [Journal-full-title] Optics express
  • [ISO-abbreviation] Opt Express
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Z4152N8IUI / Silicon
  •  go-up   go-down


62. Kellermayer R, Gyarmati J, Czakó M, Tészás A, Masszi G, Ertl T, Kosztolányi G: Mos 46,XX,r(18).ish r(18)(18ptel-,18qtel-)/46,XX.ish del(18)(18ptel-): an example for successive ring chromosome formation. Am J Med Genet A; 2005 Dec 15;139(3):234-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mos 46,XX,r(18).ish r(18)(18ptel-,18qtel-)/46,XX.ish del(18)(18ptel-): an example for successive ring chromosome formation.

  • Genetic Alliance. consumer health - Chromosome 18.
  • Genetic Alliance. consumer health - Chromosome 18, Ring.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278901.001).
  • [ISSN] 1552-4825
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Letter
  • [Publication-country] United States
  •  go-up   go-down


63. Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, Cemerikic-Martinovic V, Gotic M: Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet; 2007 Feb;173(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
  • Agnogenic myeloid metaplasia (AMM) or idiopathic myelofibrosis is a chronic myeloproliferative disorder characterized by fibrotic bone marrow, extramedullar haematopoiesis, and a leukoerythroblastic picture in circulating blood.
  • The cytogenetic data on AMM are scanty and no recurring chromosome abnormality has been associated with the natural course of this disease.
  • Trisomy 1q, del(13q), del(20q), and trisomy 8, appear in about two thirds of patients with demonstrable chromosome aberrations.
  • We report on the cytogenetic analyses of 61 consecutive patients with AMM studied at diagnosis.
  • We also detected aberrations of chromosome 13 (translocation in two and an interstitial deletion and trisomy in one patient each) and chromosome 18 (derivative 18 in two patients and a monosomy and deletion in one patient each).
  • Three patients exhibited complex aberrations involving several chromosomes, sometimes with a mosaicisam.
  • While the series of patients studied displayed chromosomal aberrations that are frequently observed in AMM, we found some new abnormalities (balanced translocations and polyploidy) that are rarely observed in AMM.
  • [MeSH-major] Cytogenetic Analysis. Primary Myelofibrosis / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284371.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Franke A, Lante W, Kollig E, Markewitz A: A comparison of monocyte counts and ex vivo and in vitro monocyte cytokine production after major surgical trauma. J Surg Res; 2009 Jun 1;154(1):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Impaired function of cluster of differentiation 14-positive (CD14+) monocytes (MOs) after major surgical trauma is believed to predispose to infectious complications.
  • RESULTS: Whereas the absolute numbers of leukocytes and CD14+ MOs were significantly elevated, HLA-DR expression was suppressed postoperatively.
  • The proportion of TNF-alpha- and IL-12-producing MOs was reduced after surgery.
  • This, however, led to a significant postoperative decrease only in the absolute numbers of peripheral blood IL-12+ MOs.
  • The IL-12-synthesizing capacity of IL-12+ MOs was significantly reduced only on d1.
  • CONCLUSIONS: The immediate postoperative period is associated with an increase in the absolute MO numbers and an impairment of MO function, which is reflected in a reduced capacity to synthesize IL-12 and TNF-alpha and a decreased ability to express HLA-DR and present antigens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952234.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Cytokines; 0 / HLA-DR Antigens; 0 / Hemoglobins; 0 / Lipopolysaccharides; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12
  •  go-up   go-down


65. Rosti V, Bonetti E, Bergamaschi G, Campanelli R, Guglielmelli P, Maestri M, Magrini U, Massa M, Tinelli C, Viarengo G, Villani L, Primignani M, Vannucchi AM, Frassoni F, Barosi G, AGIMM Investigators: High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One; 2010;5(12):e15277
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis.
  • Increased mobilization of circulating endothelial progenitor cells may represent a new biological hallmark of myeloproliferative neoplasms.
  • We measured circulating endothelial colony forming cells (ECFCs) in 106 patients with primary myelofibrosis, fibrotic stage, 49 with prefibrotic myelofibrosis, 59 with essential thrombocythemia or polycythemia vera, and 43 normal controls.
  • Increased frequency of ECFCs resulted independently associated with history of splanchnic vein thrombosis (adjusted odds ratio = 6.61, 95% CI = 2.54-17.16), and a summary measure of non-active disease, i.e. hemoglobin of 13.8 g/dL or lower, white blood cells count of 7.8×10(9)/L or lower, and platelet count of 400×10(9)/L or lower (adjusted odds ratio = 4.43, 95% CI = 1.45-13.49) Thirteen patients with splanchnic vein thrombosis non associated with myeloproliferative neoplasms were recruited as controls.
  • We concluded that increased frequency of ECFCs represents the biological hallmark of a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis.
  • The recognition of this disease category copes with the phenotypic mimicry of myeloproliferative neoplasms.
  • [MeSH-major] Endothelial Cells / cytology. Myeloproliferative Disorders / complications. Myeloproliferative Disorders / pathology. Splanchnic Circulation. Venous Thrombosis / pathology

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Nov 15;96(10):3374-80 [11071630.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Jun;31(12):1330-6 [20331577.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2752-60 [15226175.001]
  • [Cites] Q J Med. 1990 Sep;76(281):981-9 [2236481.001]
  • [Cites] Cancer. 1991 Nov 15;68(10):2310-8 [1913467.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):996-1003 [9734650.001]
  • [Cites] Br J Haematol. 1999 Mar;104(4):730-7 [10192432.001]
  • [Cites] Blood. 1951 Apr;6(4):372-5 [14820991.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5688-95 [16110028.001]
  • [Cites] Stem Cells. 2006 Feb;24(2):357-67 [16141361.001]
  • [Cites] Blood. 2006 May 1;107(9):3676-82 [16373657.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1465-72 [17082007.001]
  • [Cites] PLoS Med. 2006 Jul;3(7):e270 [16834459.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1528-34 [17133457.001]
  • [Cites] N Engl J Med. 2007 Feb 1;356(5):459-68 [17267906.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1801-9 [17053059.001]
  • [Cites] J Thromb Haemost. 2007 Apr;5(4):708-14 [17263783.001]
  • [Cites] Blood Cells Mol Dis. 2007 May-Jun;38(3):280-6 [17350297.001]
  • [Cites] Exp Hematol. 2007 Jul;35(7):1109-18 [17588480.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4030-6 [17712047.001]
  • [Cites] Blood Cells Mol Dis. 2008 Nov-Dec;41(3):284-91 [18715806.001]
  • [Cites] CA Cancer J Clin. 2009 May-Jun;59(3):171-91 [19369682.001]
  • [Cites] Acta Haematol. 2009;121(4):218-20 [19478480.001]
  • [Cites] Blood. 2010 Mar 4;115(9):1703-8 [20008785.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3249-55 [11719361.001]
  • (PMID = 21151606.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins
  • [Other-IDs] NLM/ PMC3000318
  • [Investigator] Vannucchi AM; Antonioli E; Bartalucci N; Biamonte F; Bogani C; Bosi A; Fjerza R; Guglielmelli P; Malevolti E; Pancrazzi A; Pieri L; Spolverini A; Susini MC; Tozzi L; Bortoluzzi S; Bisognin A; Coppe A; Marchioli R; Barosi G; Azzan C; Badalucco S; Balduini A; Bergamaschi G; Bonetti E; Campanelli R; Carolei A; Currao M; Isgrò MA; Lupo ML; Magrini U; Massa M; Magni V; Rosti V; Villani L; Cazzola M; Bernasconi P; Boggi S; Elena C; Gallì A; Malcovati L; Pascutto C; Passamonti F; Pietra D; Rumi E; Dejana E; Corada M; Giannotta M; Rambaldi A; Ferrari ML; Finazzi G; Finazzi MC; Magri M; Quaresmini G; Montalvo ML; Ricci C; Salmoiraghi S; Spinelli O; Amaru A; Golay J; Cilloni D; Arruga F; Bracco E; Carturan S; Gaidano V; Guerrasio A; Pradotto M; Manfredini R; Bianchi E; Montanari M; Salati S; Tagliafico E; Tenedini E; Zini R
  •  go-up   go-down


66. Rondelli D: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica; 2008 Oct;93(10):1449-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Primary Myelofibrosis / surgery

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Haematologica. 2008 Oct;93(10):1514-22 [18728030.001]
  • (PMID = 18827262.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


67. Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J: The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study. Int J Hematol; 2007 Aug;86(2):130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
  • We investigated the prevalence of the JAK2 V617F gain-of-function mutation in patients with Philadelphia chromosome-negative chronic myeloproliferative disorders (Ph- MPD) and explored the links between JAK2 mutational status and the clinicopathologic picture of essential thrombocythemia (ET), chronic idiopathic myelofibrosis (CIMF), and polycythemia vera (PV).
  • Allele-specific polymerase chain reaction results for 59 ET, 18 CIMF, and 9 PV cases were compared with values for clinical variables at presentation and last follow-up and with the diagnostic trephine bone marrow biopsy pictures.
  • JAK2 V617F was found in 38 (64%) of ET cases, 7 (39%) of CIMF cases, and 9 (100%) of PV cases.
  • Similar trends were found in CIMF.
  • Megakaryocyte clustering was much less pronounced in the CIMF cases with mutant JAK2, with an analogous trend occurring in the ET cases.
  • Bone marrow cellularity values and the numbers of CD34+ and CD117+ blasts in the ET and CIMF groups did not differ.
  • Fibrosis was slightly less marked in the ET cases with mutant JAK2.
  • The mutation did not significantly influence the clinical course during the follow-up in either disease in the short term (median follow-up, 22 months).
  • The JAK2 V617F mutation is prevalent in all Ph- MPD and may skew their presenting phenotype, including bone marrow histology, toward a more "erythremic" and less "thrombocythemic" phenotype.
  • [MeSH-major] Janus Kinase 2 / genetics. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / pathology
  • [MeSH-minor] Adult. Biopsy. Bone Marrow / pathology. Bone Marrow Examination. Female. Humans. Male. Middle Aged. Mutation, Missense. Phenotype. Polycythemia Vera / genetics. Polycythemia Vera / pathology. Primary Myelofibrosis / genetics. Primary Myelofibrosis / pathology. Thrombocythemia, Essential / genetics. Thrombocythemia, Essential / pathology

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] Mol Biol Cell. 2003 Apr;14(4):1448-59 [12686600.001]
  • [Cites] Blood. 1999 Jan 15;93(2):417-24 [9885203.001]
  • [Cites] Int J Hematol. 2002 Aug;76(2):133-45 [12215011.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Lancet. 2005 Dec 3;366(9501):1945-53 [16325696.001]
  • [Cites] Semin Hematol. 1975 Oct;12 (4):409-32 [1105793.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):631-5 [16369984.001]
  • [Cites] Semin Hematol. 1997 Jan;34(1):29-39 [9025160.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2920-1 [16204151.001]
  • [Cites] Mayo Clin Proc. 1998 Dec;73(12):1177-84 [9868417.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2098-100 [16293597.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):244-5 [16398659.001]
  • [Cites] Mayo Clin Proc. 2004 Jul;79(7):953-4 [15244400.001]
  • [Cites] Ann Hematol. 2001 Mar;80(3):160-5 [11320901.001]
  • [Cites] Acta Haematol. 2005;114(1):7-25 [15995322.001]
  • [Cites] Ann Hematol. 2003 Mar;82(3):148-52 [12634946.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22788-92 [15863514.001]
  • [Cites] Leuk Lymphoma. 1996 Sep;22 Suppl 1:87-93 [8951778.001]
  • [Cites] Br J Haematol. 2005 Nov;131(3):320-8 [16225651.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):208-13 [16197451.001]
  • [Cites] Semin Hematol. 1975 Oct;12(4):339-51 [1198126.001]
  • [Cites] Cancer. 1991 May 15;67(10):2658-63 [2015567.001]
  • [Cites] Haematologica. 2000 May;85(5):492-5 [10800165.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):797-9 [16115143.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):132-9 [10966175.001]
  • [Cites] Pol J Pathol. 2004;55(1):13-23 [15195702.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Cell. 1998 May 1;93(3):385-95 [9590173.001]
  • [Cites] Am J Clin Pathol. 1971 Jul;56(1):24-31 [5556211.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1207-9 [15860661.001]
  • [Cites] Mayo Clin Proc. 2005 Jul;80(7):947-58 [16007902.001]
  • (PMID = 17875526.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


68. Reilly JT: Prognosis and survivorship in primary myelofibrosis. Am J Hematol; 2010 Jan;85(1):4-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and survivorship in primary myelofibrosis.
  • [MeSH-major] Patient Selection. Primary Myelofibrosis / diagnosis. Severity of Illness Index
  • [MeSH-minor] Chromosome Aberrations. Disease-Free Survival. Humans. Prognosis. Risk Factors. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Hematol. 2010 Jan;85(1):14-7 [20029953.001]
  • (PMID = 20029947.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


69. Evans CL, Maine D, McCloskey L, Feeley FG, Sanghvi H: Where there is no obstetrician--increasing capacity for emergency obstetric care in rural India: an evaluation of a pilot program to train general doctors. Int J Gynaecol Obstet; 2009 Dec;107(3):277-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Where there is no obstetrician--increasing capacity for emergency obstetric care in rural India: an evaluation of a pilot program to train general doctors.
  • In 2006, the Government of India and the Federation of Obstetric and Gynecological Societies of India (FOGSI) with technical assistance from Jhpiego, instituted a nationwide, 16-week comprehensive EmOC (CEmOC) training program for general medical officers (MOs).
  • CONCLUSION: Although MOs can be trained to provide CEmOC (including cesarean delivery), without proper selection of facilities and trainees, adequate training, and support, this strategy will not substantially improve the availability of comprehensive EmOC in India.

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Childbirth Problems.
  • MedlinePlus Health Information. consumer health - Rural Health Concerns.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19846091.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Franck LS, Harris SK, Soetenga DJ, Amling JK, Curley MA: The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients. Pediatr Crit Care Med; 2008 Nov;9(6):573-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: Eighty-three pediatric patients, median age 35 mos (interquartile range: 7 mos-10 yrs), recovering from acute respiratory failure who were being weaned from more than 5 days of continuous infusion or round-the-clock opioid and benzodiazepine administration.
  • A total of 1040 withdrawal symptom assessments were completed, with a median (interquartile range) of 11 (6-16) per patient over 6.6 (4.8-11) days.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anesth Analg. 2006 Apr;102(4):1045-50 [16551896.001]
  • [Cites] Intensive Care Med. 2007 Aug;33(8):1396-406 [17541548.001]
  • [Cites] J Intensive Care Med. 2007 May-Jun;22(3):173-9 [17569173.001]
  • [Cites] Paediatr Anaesth. 2007 Jul;17(7):675-83 [17564650.001]
  • [Cites] Intensive Care Med. 2006 Aug;32(8):1125-36 [16699772.001]
  • [Cites] Pediatr Crit Care Med. 2006 Mar;7(2):107-14 [16446601.001]
  • [Cites] Intensive Crit Care Nurs. 2004 Dec;20(6):344-51 [15567675.001]
  • [Cites] Pediatr Crit Care Med. 2004 Nov;5(6):521-32 [15530187.001]
  • [Cites] Crit Care Med. 1999 Jan;27(1):196-9 [9934916.001]
  • [Cites] Am J Crit Care. 1998 Sep;7(5):364-9 [9740886.001]
  • [Cites] J Dev Behav Pediatr. 1998 Apr;19(2):89-93 [9584937.001]
  • [Cites] Crit Care Med. 1996 May;24(5):743-52 [8706448.001]
  • [Cites] Crit Care Med. 1994 Feb;22(2):334-42 [8306694.001]
  • [Cites] J Pediatr. 1992 Jul;121(1):68-74 [1625096.001]
  • [Cites] Crit Care Med. 2002 Jan;30(1):119-41 [11902253.001]
  • [Cites] Intensive Care Med. 2000 Mar;26(3):275-85 [10823383.001]
  • [Cites] Crit Care Med. 2000 Jun;28(6):2122-32 [10890677.001]
  • [CommentIn] Pediatr Crit Care Med. 2008 Nov;9(6):654-5 [18997597.001]
  • (PMID = 18838937.001).
  • [ISSN] 1529-7535
  • [Journal-full-title] Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
  • [ISO-abbreviation] Pediatr Crit Care Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / 1R21HD045020; United States / NICHD NIH HHS / HD / R21 HD045020-01; United States / NICHD NIH HHS / HD / HD045020-02; United States / NICHD NIH HHS / HD / R21 HD045020; United States / NICHD NIH HHS / HD / HD045020-01; United States / NICHD NIH HHS / HD / R21 HD045020-02
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 12794-10-4 / Benzodiazepines
  • [Other-IDs] NLM/ NIHMS78618; NLM/ PMC2775493
  •  go-up   go-down


76. Wada N, Sakai H: Decomposition reaction of dioxetanone in firefly bioluminescence by computer experiment. J Biol Phys; 2005 Dec;31(3-4):403-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The S(1)-PEC relative to S(0)-PEC was estimated at each point of the reaction coordinate using the INDO/S, where only the singly-excited configuration interactions (CI) constructed from 20 occupied and 20 unoccupied molecular orbitals (MOs) were considered.
  • As a result of these calculations, it was concluded that (1) firefly dioxetanone might not be an intermediate but rather be in an unstable transition state;.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1978 Jan;75(1):30-3 [272645.001]
  • [Cites] Photochem Photobiol. 1995 Oct;62(4):607-14 [7480147.001]
  • (PMID = 23345906.001).
  • [ISSN] 0092-0606
  • [Journal-full-title] Journal of biological physics
  • [ISO-abbreviation] J Biol Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3456329
  • [Keywords] NOTNLM ; dioxetanone / firefly bioluminescence / oxyluciferin / semiempirical molecular orbital method / transition state
  •  go-up   go-down


77. Abdelgadir M, Shebeika W, Eltom M, Berne C, Wikblad K: Health related quality of life and sense of coherence in Sudanese diabetic subjects with lower limb amputation. Tohoku J Exp Med; 2009 Jan;217(1):45-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally the Sense of Coherence scale (SOC-13) and a symptom check list was used in subjects with LLA.
  • For both groups HRQOL was measured using The Medical Outcomes Study questionnaire (MOS).

  • MedlinePlus Health Information. consumer health - Diabetes.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155607.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


78. Gulen H, Basarir F, Hakan N, Ciftdogan DY, Tansug N, Onag A: Premature labor and leukoerythroblastosis in a newborn with parvovirus B19 infection. Haematologica; 2005 Nov;90 Suppl:ECR38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leukoerythroblastosis is a rarely observed disease characterized by the presence of leukocytosis, erythroid and myeloid blast cells in peripheral blood.
  • Bone marrow cytogenetic examination was normal.
  • Parvovirus B19 Ig G and M serology were detected to be positive.
  • As a result, premature delivery and leukoerythroblastosis were thought to have developed secondary to intrauterine parvovirus B19 infection.
  • Leukoerythroblastosis is a rarely observed disease characterized by the presence of leukocytosis, erythroid and myeloid blast cells in peripheral blood.
  • It is reported that it can be observed following hematologic malignancies especially juvenile myelomonocytic leukemia, acute infections, hemolytic anemia, osteopetrosis, myelofibrosis, neuroblastoma and taking certain medicines.
  • Here we the case of a newborn who was referred to our intensive care unit due to being born prematurely at the 29th week of gestation and diagnosed with leukoerythroblastosis.

  • MedlinePlus Health Information. consumer health - Premature Babies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266929.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


79. Guglielmelli P, Vannucchi AM: Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms. F1000 Med Rep; 2010;2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms.
  • The Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) have recently been the focus of tremendous advances in basic knowledge of disease pathophysiology following the recognition of mutations in JAK2 and MPL.
  • These discoveries also led to refinement of the criteria employed for diagnosis.
  • A new risk stratification approach to the patient with primary myelofibrosis allows clinicians to distinguish categories of patients with significantly different expected survival.
  • Finally, new drugs are currently being tested for MPNs, and molecular discoveries could ultimately lead to the development of a specific targeted therapy.
  • Overall, significant advances in diagnosis, prognostication, and treatment have taken place in the last couple of years in the field of MPNs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948870.001).
  • [ISSN] 1757-5931
  • [Journal-full-title] F1000 medicine reports
  • [ISO-abbreviation] F1000 Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2948376
  •  go-up   go-down


80. Carod-Artal FJ, Coral LF, Trizotto DS, Moreira CM: The stroke impact scale 3.0: evaluation of acceptability, reliability, and validity of the Brazilian version. Stroke; 2008 Sep;39(9):2477-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Health-related quality of life was evaluated with the MOS-Short Form 36 and SIS 3.0.
  • Regarding convergent validity, a significant correlation (Spearman's correlation coefficient, P<0.0001) was found between the SIS composite physical domain and the National Institutes of Health Stroke Scale (-0.69), modified Rankin Scale (-0.81), Barthel Index (0.87), Lawton Scale (0.76), and MOS-Short Form 36 physical component summary (0.61).
  • [MeSH-major] Disability Evaluation. Stroke / diagnosis
  • [MeSH-minor] Activities of Daily Living. Adult. Aged. Brazil / epidemiology. Female. Hand / innervation. Hand / physiopathology. Health Status Indicators. Humans. Male. Middle Aged. Muscle Weakness / diagnosis. Muscle Weakness / rehabilitation. Paresis / diagnosis. Paresis / rehabilitation. Psychometrics. Reproducibility of Results. Risk Factors

  • MedlinePlus Health Information. consumer health - Stroke.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635846.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


81. Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, Kastritis E, Gika D, Skarlos D, Linardou H, Kalofonos HP, Dimopoulos MA: The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer; 2006 Jan 15;106(2):297-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Sixty patients (49 men and 11 women, with a median age of 69 yrs) were enrolled in the current study.
  • The median time to disease progression was 7.6 months (95% CI, 4.5-10.7 mos) and the median overall survival was 16.3 months (95% CI, 12-20.6 mos).

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342065.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


82. Morrogh M, Miner TJ, Park A, Jenckes A, Gonen M, Seidman A, Morrow M, Jaques DP, King TA: A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer. Cancer; 2010 Jul 15;116(14):3338-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At study entry, patients had received a mean of 6 prior systemic therapies for metastatic disease.
  • At a median survival of 37.4 mos from MBC diagnosis (range, 1.6-164 months) and 8.4 months after intervention (range, 0.2-73 months), 7 of 91 patients remained alive.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Metastasis. Quality of Life. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564060.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS661516; NLM/ PMC4465203
  •  go-up   go-down


83. Jaeckle KA, Ballman KV, Giannini C, Schomberg PJ, Ames MM, Reid JM, McGovern RM, Safgren SL, Galanis E, Uhm JH, Brown PD, Hammack JE, Arusell R, Nikcevich DA, Morton RF, Wender DB, Buckner JC: Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM. J Neurooncol; 2010 Aug;99(1):73-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MTD for non-EIAC patients was as follows: irinotecan 125 mg/m(2)/week on Days 1, 8, 22 and 29 during RT, followed by BCNU 100 mg/m(2) Day 1 and irinotecan 75 mg/m(2) Days 1, 8, 22 and 29, every 6 weeks.
  • Median OS was 10.8 mos. (95% CI: 7.7-14.9); OS at 12 months was 44.6% (95% CI: 33.3-59.8) and PFS 6 was 28.6% (95% CI: 18.9-43.2).
  • Patients went off treatment due to adverse events (7%), refusal (11%), progressive disease (48%), death (9%), and other (9%); 16% completed protocol treatment.
  • Grade 3-4 toxicity was more common in non-EIAC patients with variant alleles.
  • SN-38 C(max) and AUC in EIAC patients receiving 400 mg/m(2) irinotecan were 20.9 ng/ml and 212 ng/ml h, and in non-EIAC patients receiving 125 mg/m(2), 15.5 ng/ml and 207 ng/ml h.
  • SN-38 AUC varied by UGT1A1*28 status in non-EIAC patients.
  • Non-EIAC patients with UGT1A1*28 variant alleles appear particularly sensitive to toxicity from irinotecan.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 1997;40(3):259-65 [9219511.001]
  • [Cites] Drug Metab Dispos. 1997 Oct;25(10):1157-64 [9321519.001]
  • [Cites] Clin Pharmacol Ther. 1997 Sep;62(3):287-92 [9333104.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):485-90 [9554593.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):845-7 [9789606.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):785-8 [9845096.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Clin Pharmacol Ther. 1999 May;65(5):576-82 [10340924.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5294-304 [15998902.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4675-86 [17214326.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):606-13 [17577234.001]
  • [Cites] J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5 [17728214.001]
  • [Cites] J Neurooncol. 2009 Apr;92(2):165-75 [19066728.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):345-9 [10755324.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):204-8 [11943904.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):33-40 [12199631.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):603-14 [12649109.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2352-8 [12712456.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Cancer Treat Rep. 1983 Feb;67(2):121-32 [6337710.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Jpn J Cancer Res. 1997 Feb;88(2):218-23 [9119752.001]
  • [Cites] Radiother Oncol. 1997 May;43(2):197-201 [9192967.001]
  • (PMID = 20063115.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA035113-24; United States / NCI NIH HHS / CA / U10 CA035267; United States / NCI NIH HHS / CA / CA035101-24; United States / NCI NIH HHS / CA / U10 CA052352; United States / NCI NIH HHS / CA / U10 CA037417; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA035269; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / U10 CA035267-24; United States / NCI NIH HHS / CA / CA063848-16; United States / NCI NIH HHS / CA / U10 CA025224-24; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / U10 CA035113-24; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / CA037417-24; United States / NCI NIH HHS / CA / CA035431-24; United States / NCI NIH HHS / CA / U10 CA063848-16; United States / NCI NIH HHS / CA / CA052352-20; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / U10 CA037404-16; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / U10 CA035431-24; United States / NCI NIH HHS / CA / CA037404-16; United States / NCI NIH HHS / CA / CA035103-24; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035101; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / U10 CA035269-24; United States / NCI NIH HHS / CA / CA035267-24; United States / NCI NIH HHS / CA / CA025224-24; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / U10 CA037417-24; United States / NCI NIH HHS / CA / U10 CA035103-24; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / UG1 CA189808; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA035269-24; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035101-24; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / U10 CA052352-20; United States / NCI NIH HHS / CA / U10 CA035103
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; U68WG3173Y / Carmustine; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS197040; NLM/ PMC2897141
  •  go-up   go-down


84. Cox CE, Docherty SL, Brandon DH, Whaley C, Attix DK, Clay AS, Dore DV, Hough CL, White DB, Tulsky JA: Surviving critical illness: acute respiratory distress syndrome as experienced by patients and their caregivers. Crit Care Med; 2009 Oct;37(10):2702-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We conducted semistructured interviews with 23 acute respiratory distress syndrome survivors and 24 caregivers 3 to 9 mos after intensive care unit admission, stopping enrollment after thematic saturation was reached.
  • SETTING: Medical and surgical intensive care units of an academic medical center and a community hospital.
  • [MeSH-minor] Adaptation, Psychological. Adult. Aged. Body Image. Cost of Illness. Culture. Disability Evaluation. Empathy. Female. Follow-Up Studies. Humans. Male. Mental Recall. Middle Aged. Outcome Assessment (Health Care). Patient Care Team. Self Concept. Sick Role. Social Support. Stress Disorders, Post-Traumatic / diagnosis. Stress Disorders, Post-Traumatic / psychology


85. Parameswaran P, Frenking G: Transition-metal complexes [(PMe(3))(2)Cl(2)M(E)] and [(PMe(3))(2)(CO)(2)M(E)] with naked group 14 atoms (E=C-Sn) as ligands; part 1: parent compounds. Chemistry; 2009 Sep 7;15(35):8807-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transition-metal complexes [(PMe(3))(2)Cl(2)M(E)] and [(PMe(3))(2)(CO)(2)M(E)] with naked group 14 atoms (E=C-Sn) as ligands; part 1: parent compounds.
  • The equilibrium geometries and bond dissociation energies of 16-valence-electron(VE) complexes [(PMe(3))(2)Cl(2)M(E)] and 18-VE complexes [(PMe(3))(2)(CO)(2)M(E)] with M=Fe, Ru, Os and E=C, Si, Ge, Sn were calculated by using density functional theory at the BP86/TZ2P level.
  • Thus, the bonding situation is intermediate between a typical Fischer complex and a Schrock complex.
  • The shape of the frontier orbitals reveals that the HOMO-2 sigma MO and the LUMO and LUMO+1 pi* MOs of 1ME are very similar to the frontier orbitals of CO.


86. Pieri L, Guglielmelli P, Vannucchi AM: Chronic myeloproliferative neoplasms: a collaborative approach. Mediterr J Hematol Infect Dis; 2010;2(2):e2010017
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic myeloproliferative neoplasms: a collaborative approach.
  • The classic chronic myeloproliferative neoplasms (MPN) include different entities that pose significant challenges for their optimal diagnosis, treatment and overall management.
  • Polycythemia Vera and Essential Thrombocythemia are the most common among chronic myeloproliferative neoplasms (MPNs); major causes of morbidity and mortality are represented by arterial and venous thrombosis, as well as evolution to myelofibrosis or transformation to acute leukemia.
  • On the other hand, survival is significantly reduced in primary myelofibrosis, and the clinical manifestations may be disabling.
  • In the absence of therapies with the potential of curing the disease, a careful risk-oriented approach is employed for stratifying patients to the most appropriate, currently available, therapeutic options.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Mol Med. 2009 Aug;13(8A):1437-50 [19522842.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4563-9 [19652059.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4760-6 [19720904.001]
  • [Cites] Haematologica. 2004 Feb;89(2):215-32 [15003898.001]
  • [Cites] Br J Haematol. 2005 May;129(3):293-306 [15842653.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:246-52 [17124068.001]
  • [Cites] Blood. 2009 May 28;113(22):5394-400 [19332765.001]
  • [Cites] Leukemia. 2008 Jan;22(1):23-30 [17882282.001]
  • [Cites] Leukemia. 2008 Apr;22(4):740-7 [18079739.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1628-37 [18566326.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1494-502 [18596737.001]
  • [Cites] Blood Rev. 2008 Sep;22(5):235-45 [18617299.001]
  • [Cites] Leukemia. 2008 Nov;22(11):1990-8 [18843285.001]
  • [Cites] Blood. 2007 Jul 15;110(2):485-9 [17426257.001]
  • (PMID = 21415968.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033142
  •  go-up   go-down


87. Guglielmelli P, Barosi G, Pieri L, Antonioli E, Bosi A, Vannucchi AM: JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica; 2009 Jan;94(1):144-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.


88. Cutting RJ, Welch E, Channer J, Ezaydi Y, Talley P, Reilly JT, Snowden JA: Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: failure of a lasting response to a second allogeneic transplant from the original donor. Bone Marrow Transplant; 2008 Nov;42(9):631-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: failure of a lasting response to a second allogeneic transplant from the original donor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Myelodysplastic Syndromes / etiology. Primary Myelofibrosis / etiology. Tissue Donors
  • [MeSH-minor] Adult. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Transplantation Conditioning


89. Hiura A, Nakagawa H: Induction of corneal lesion and nerve fiber sprouting by neonatal capsaicin application depends on the dose of the drug and survival time after treatment. Okajimas Folia Anat Jpn; 2005 Aug;82(2):57-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of capsaicin on the rat cornea and its NsAchE (non specific acetylcholinesterase)-positive nerve fibers were investigated after long and short survival periods following subcutaneous (s.c) injection of the drug.
  • After 4 (n = 6), 8 (n = 6) and 12 (n = 4) mos., both sides of the corneas were examined under a binocular microscope to look for corneal abnormalities.
  • Immediately after the enucleation, bilateral corneas were excised with a thin scleral margin and their ciliary body and iris were removed in DPBS solution.
  • Corneal lesions and sprouting of the NsAchE-positive subepithelial nerve fibers appeared 4 mos. after the treatment with capsaicin (50 mg/kg).
  • In particular, all the treated corneas (8/8) at 12 mos. showed corneal abnormalities.

  • Hazardous Substances Data Bank. CAPSAICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16212277.001).
  • [ISSN] 0030-154X
  • [Journal-full-title] Okajimas folia anatomica Japonica
  • [ISO-abbreviation] Okajimas Folia Anat Jpn
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] S07O44R1ZM / Capsaicin
  •  go-up   go-down


90. Araki N, Takimoto R, Chiba H, Araki H, Sato T, Iyama S, Hirakawa M, Ono K, Kawano Y, Takada K, Miyanishi K, Kobune M, Matsunaga T, Kato J, Nakamura T, Niitsu Y: [Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation]. Rinsho Ketsueki; 2007 Jul;48(7):554-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient's red blood cell volume was 33 ml/kg and bone marrow cytology was able to rule out other myeloproliferative diseases such as chronic myelogenous leukemia, essential thrombocytosis and myelofibrosis.


91. Sivelli R, Piccolo D, Soliani P, Franzini C, Ziegler S, Sianesi M: [Rupture of the spleen in angiosarcoma: a case report and review of the literature]. Chir Ital; 2005 May-Jun;57(3):377-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a patient admitted in a state of hypovolaemic shock with haemoperitoneum due to rupture of the spleen.
  • Splenic angiosarcoma should be suspected in cases of splenomegaly with unknown anaemia and no lymphoma, leukaemia or myelofibrosis, because of its neoplastic aggressiveness and its invariably fatal outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231829.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 11
  •  go-up   go-down


92. Ferhi K, Rouprêt M, Rode J, Misrai V, Renard-Penna R, Conort P, Bitker MO, Haertig A, Chartier-Kastler E, Richard F, Vaessen C: Promising functional outcomes obtained with robot-assisted laparoscopic pyeloplasty: a single-center experience. J Endourol; 2009 Jun;23(6):959-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty patients with a mean age of 36.8 +/- 16 years (range 15-69 yr) were included.
  • The mean follow-up was 19.9 +/- 10.03 months (range 3-37 mos).

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473067.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Lasker DA, Evans EM, Layman DK: Moderate carbohydrate, moderate protein weight loss diet reduces cardiovascular disease risk compared to high carbohydrate, low protein diet in obese adults: A randomized clinical trial. Nutr Metab (Lond); 2008;5:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Moderate carbohydrate, moderate protein weight loss diet reduces cardiovascular disease risk compared to high carbohydrate, low protein diet in obese adults: A randomized clinical trial.
  • Adults (n = 50, 47 +/- 7 y) matched on BMI (33.6 +/- 0.6 kg/m2, P = 0.79) consumed energy restricted diets (deficit ~500 kcal/d): PRO (1.6 g.kg-1.d-1 protein and < 170 g/d carbohydrate) or CHO (0.8 g.kg-1.d-1 protein and > 220 g/d carbohydrate) for 4 mos.
  • RESULTS: There was a trend for PRO to lose more weight (-9.1% vs. -7.3%, P = 0.07) with a significant reduction in percent fat mass compared to CHO (-8.7% vs. -5.7%; P = 0.03).
  • CONCLUSION: A weight loss diet with moderate carbohydrate, moderate protein results in more favorable changes in body composition, dyslipidemia, and post-prandial INS response compared to a high carbohydrate, low protein diet suggesting an additional benefit beyond weight management to include augmented risk reduction for metabolic disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2003 Feb;133(2):411-7 [12566476.001]
  • [Cites] Am J Clin Nutr. 2003 Jul;78(1):31-9 [12816768.001]
  • [Cites] J Nutr. 2003 Jan;133(1):261S-267S [12514305.001]
  • [Cites] Acta Diabetol. 2002 Dec;39(4):215-20 [12486496.001]
  • [Cites] Circulation. 2000 Oct 31;102(18):2284-99 [11056107.001]
  • [Cites] Am J Clin Nutr. 2000 Feb;71(2):412-33 [10648253.001]
  • [Cites] Am J Clin Nutr. 2008 May;87(5):1571S-1575S [18469290.001]
  • [Cites] Diabetes Care. 2007 Feb;30(2):263-9 [17259492.001]
  • [Cites] Am J Clin Nutr. 2006 Oct;84(4):813-21 [17023708.001]
  • [Cites] Int J Cardiol. 2006 Jun 16;110(2):212-6 [16297472.001]
  • [Cites] Cardiol Rev. 2005 Nov-Dec;13(6):322-7 [16708441.001]
  • [Cites] Am J Clin Nutr. 2006 May;83(5):1025-31; quiz 1205 [16685042.001]
  • [Cites] J Nutr. 2006 Feb;136(2):384-9 [16424116.001]
  • [Cites] J Nutr. 2006 Jan;136(1 Suppl):319S-23S [16365106.001]
  • [Cites] J Nutr. 2005 Aug;135(8):1903-10 [16046715.001]
  • [Cites] Am J Clin Nutr. 2005 Jun;81(6):1298-306 [15941879.001]
  • [Cites] Am J Clin Nutr. 2005 May;81(5):976-82 [15883418.001]
  • [Cites] Am J Clin Nutr. 2005 May;81(5):949-50 [15883413.001]
  • [Cites] Br J Nutr. 2005 Feb;93(2):281-9 [15788122.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Mar;34(1):49-62 [15752921.001]
  • [Cites] Diabetologia. 2005 Jan;48(1):8-16 [15616799.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Metabolism. 1991 Apr;40(4):338-43 [2011075.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Clin Lab Med. 1989 Mar;9(1):105-35 [2538292.001]
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] J Clin Invest. 1967 Nov;46(11):1756-67 [6061748.001]
  • [Cites] Diabetes. 2004 Sep;53(9):2375-82 [15331548.001]
  • [Cites] JAMA. 2004 Jun 16;291(23):2847-50 [15199035.001]
  • [Cites] J Am Coll Nutr. 2004 Apr;23(2):177-84 [15047685.001]
  • [Cites] J Nutr. 2004 Apr;134(4):968S-73S [15051856.001]
  • [Cites] J Nutr. 2004 Apr;134(4):880-5 [15051841.001]
  • [Cites] Endocrinol Metab Clin North Am. 2003 Dec;32(4):855-67 [14711065.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2756-61 [12949361.001]
  • [Cites] J Nutr. 2003 Feb;133(2):405-10 [12566475.001]
  • (PMID = 18990242.001).
  • [ISSN] 1743-7075
  • [Journal-full-title] Nutrition & metabolism
  • [ISO-abbreviation] Nutr Metab (Lond)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2585565
  •  go-up   go-down


94. Carod-Artal FJ, Martinez-Martin P, Vargas AP: Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. Mov Disord; 2007 Jan;22(1):91-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to perform an independent validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial questionnaire (SCOPA-PS) and assessment of the Parkinson's Disease Questionnaire (PDQ-39), Brazilian version.
  • Patients were evaluated by means of the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr staging (HY), Schwab and England scale, Mini-Mental State Examination, and Hospital Anxiety and Depression Scale.
  • Health-related quality of life was evaluated using the MOS-Short Form 36 (SF-36), PDQ-39, and SCOPA-PS.
  • [MeSH-major] Parkinson Disease / diagnosis. Parkinson Disease / psychology. Psychiatric Status Rating Scales. Psychometrics. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Movement Disorder Society.
  • (PMID = 17094102.001).
  • [ISSN] 0885-3185
  • [Journal-full-title] Movement disorders : official journal of the Movement Disorder Society
  • [ISO-abbreviation] Mov. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


95. Andreozzi GM, Cordova RM, Scomparin A, Martini R, D'Eri A, Andreozzi F, Quality of Life Working Group on Vascular Medicine of SIAPAV: Quality of life in chronic venous insufficiency. An Italian pilot study of the Triveneto Region. Int Angiol; 2005 Sep;24(3):272-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in chronic venous insufficiency. An Italian pilot study of the Triveneto Region.
  • AIM: Chronic venous insufficiency (CVI) is a chronic disease, whose disability has not been appreciated clearly, and several treatment costs are not covered by Public Health Service, probably because its any social impact is not well known.
  • METHODS: One hundred and four patients with CVI received the Italian version of four QoL assessment instruments (MOS SF-36; CIVIQ-2; Euro-QoL 5D and a visual analogical scale).
  • After filling the questionnaires, patients underwent a clinical and instrumental examination to assess the diagnosis according to the CEAP classification.
  • This early involvement of physical items underlines how CVI is not an esthetic problem, but, a disease.
  • Its impact on the lifestyle and QoL is similar to that of other chronic diseases (diabetes, cancer, chronic pulmonary disease), reaching in the class C5-6 the poorest level, similar to heart failure.
  • [MeSH-minor] Aged. Chronic Disease. Humans. Italy. Life Style. Middle Aged. Pain Measurement. Pilot Projects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158038.001).
  • [ISSN] 0392-9590
  • [Journal-full-title] International angiology : a journal of the International Union of Angiology
  • [ISO-abbreviation] Int Angiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


96. Rangan V, Ghosh A, Aparin V, Cauwenberghs G: A subthreshold aVLSI implementation of the Izhikevich simple neuron model. Conf Proc IEEE Eng Med Biol Soc; 2010;2010:4164-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Log-domain circuit design utilizing MOS transistors in subthreshold results in high energy efficiency, with less than 1pJ of energy consumed per spike.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21096884.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Sheth F, Ewers E, Kosyakova N, Weise A, Sheth J, Desai M, Andrieux J, Vermeesch J, Hamid AB, Ziegler M, Liehr T: A small supernumerary marker chromosome present in a Turner syndrome patient not derived from X- or Y-chromosome: a case report. Mol Cytogenet; 2009;2:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Small supernumerary marker chromosomes (sSMC) can be present in numerically abnormal karyotypes like in a 'Turner-syndrome karyotype' mos 45,X/46,X,+mar.
  • According to cytogenetic and molecular cytogenetic characterization the karyotype was 46,X,+del(14)(q11.1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Dev. 2007;1(6):353-62 [18391547.001]
  • [Cites] Cytogenet Genome Res. 2006;112(1-2):23-34 [16276087.001]
  • [Cites] Clin Genet. 2001 Jul;60(1):73-6 [11531974.001]
  • [Cites] Genet Med. 2004 May-Jun;6(3):132-5 [15354330.001]
  • [Cites] Cytogenet Genome Res. 2004;107(1-2):55-67 [15305057.001]
  • [Cites] Baillieres Clin Haematol. 1991 Apr;4(2):391-428 [1680511.001]
  • (PMID = 19909521.001).
  • [ISSN] 1755-8166
  • [Journal-full-title] Molecular cytogenetics
  • [ISO-abbreviation] Mol Cytogenet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2779184
  •  go-up   go-down


98. Mesa RA: Assessing new therapies and their overall impact in myelofibrosis. Hematology Am Soc Hematol Educ Program; 2010;2010:115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing new therapies and their overall impact in myelofibrosis.
  • Clinical management of myelofibrosis (MF)--whether primary or arising from an antecedent myeloproliferative neoplasm (post-essential thrombocythemia/polycythemia vera MF)--is currently in a period of transition that began with the discovery of the JAK2-V617F mutation 5 years ago.
  • Enhanced prognostic modeling systems are helping us to better characterize prognosis in MF patients not only at diagnosis, but also along the dynamic and variable course of the illness.

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21239780.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  •  go-up   go-down


99. Wolfe F, Michaud K, Li T: Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol; 2006 Oct;33(10):1942-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We evaluated 8676 patients with RA and a comparison group of 1364 subjects with non-fibromyalgia, noninflammatory disorders (NID) using the Medical Outcome Study (MOS) sleep questionnaire, including 2 MOS sleep problem indexes (SPI-I, SPI-II) and the MOS SD scale.
  • RESULTS: The scales had similar mean values: SPI-I 35.4 (19.4), SPI-II 36.0 (19.1), SDS 35.0 (24.7), and VAS sleep 36.1 (29.7), and the values for the MOS scales exceeded population norms by 25% (VAS by 42%).
  • The VAS scale was more strongly associated with RA clinical variables than the MOS scales; however, the distributional characteristics of the scales differed, with the VAS scales capturing more extreme values.
  • SD is linked to pain, mood, and disease activity.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • MedlinePlus Health Information. consumer health - Sleep Disorders.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16960928.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; OP401G7OJC / Etanercept
  •  go-up   go-down


100. Harrison CN: Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol; 2005 Jul;130(2):153-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This condition is dominated by thrombotic and haemorrhagic complications and, in the long-term, by risk of transformation to myelofibrosis and/or acute leukaemia.
  • Here, a review of current concepts in disease aetiology and management is offered with reference to recent focused reviews where appropriate.
  • In addition, five specific areas are discussed in detail: the role of the trephine biopsy, the disease entity prefibrotic myelofibrosis; the recently described Janus kinase 2 (JAK2) mutations; the leukaemogenicity of hydroxyurea (hydroxycarbamide); and lastly, the implications of the results of the Medical Research Council Primary Thrombocythaemia 1 study are explored.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Haematol. 2005 Aug;130(3):465
  • (PMID = 16029444.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 121
  •  go-up   go-down






Advertisement